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http://dx.doi.org/10.1016/j.ccell.2017.07.007SUMMARYWe performed integrated genomic, transcriptomic, and proteomic profiling of 150 pancreatic ductal adeno-
carcinoma (PDAC) specimens, including samples with characteristic low neoplastic cellularity. Deep whole-
exome sequencing revealed recurrent somatic mutations inKRAS, TP53,CDKN2A, SMAD4,RNF43,ARID1A,
TGFbR2,GNAS,RREB1, andPBRM1.KRASwild-type tumorsharboredalterations inother oncogenicdrivers,
including GNAS, BRAF, CTNNB1, and additional RAS pathway genes. A subset of tumors harbored multiple
KRAS mutations, with some showing evidence of biallelic mutations. Protein profiling identified a favorable
prognosis subset with low epithelial-mesenchymal transition and high MTOR pathway scores. Associations
of non-coding RNAs with tumor-specific mRNA subtypes were also identified. Our integrated multi-platform
analysis reveals a complex molecular landscape of PDAC and provides a roadmap for precision medicine.INTRODUCTION
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive dis-
ease that typically presents at an advanced stage and is refrac-
tory to most treatment modalities (Ryan et al., 2014; Wolfgang
et al., 2013). PDAC is predicted to become the second leading
cause of cancer mortality by the year 2030 (Rahib et al., 2014).
Characterization of the recurrent genetic alterations in PDAC
has yielded important insights into the biology of this disease,
an improved understanding of familial predisposition, and a
foundation for developing approaches for early detection and
improved therapies. The first whole-exome sequencing study
of pancreatic cancer identified a large number of mutations
and somatic copy number alterations (SCNAs) that alter the
function of many key oncogenes and tumor suppressor genes,
including KRAS, TP53, SMAD4, and CDKN2A (Jones et al.,
2008). Follow-up whole-exome and whole-genome studies vali-
dated these findings and revealed a ‘‘long tail’’ of less prevalent
alterations in other genes, such as those coding for regulators of
axon guidance (Bailey et al., 2016; Biankin et al., 2012; WaddellSignificance
Pancreatic cancer is a devastating disease with few therapeutic
150 pancreatic cancer specimens, including DNA alterations;
expression profiles. We employed a rigorous approach to anal
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damage repair genes such as BRCA1, BRCA2, PALB2, or ATM
give rise to genomic instability in a subset of PDACs and could
make them more sensitive to platinum-based chemotherapy
(Roberts et al., 2016; Sahin et al., 2016a; Waddell et al., 2015).
Furthermore, recent sequencing of neoplastic cell-enriched
whole genomes has demonstrated that the majority of PDACs
harbor complex chromosomal rearrangement patterns, some
of which are consistent with a catastrophic model of PDAC pro-
gression (Notta et al., 2016). Gene expression studies have iden-
tified subtypes of PDACwith prognostic and biological relevance
(Bailey et al., 2016; Collisson et al., 2011; Moffitt et al., 2015).
PDACs are characterized by a prominent desmoplastic reac-
tion with a dense fibrotic stroma (Iacobuzio-Donahue et al.,
2002), and a typical primary pancreatic cancer often demon-
strates only 5%–20% neoplastic cellularity (Wood and Hruban,
2012). This low tumor cellularity has confounded the analyses
of mutational and gene expression features of the actual
neoplastic cells. Given this, prior genome sequencing studies
have focused on tumors with neoplastic cellularity typicallyoptions.We present a comprehensivemolecular analysis of
DNA methylation; and mRNA, miRNA, lncRNA, and protein
yze tumors with low neoplastic cellularity, a common feature
nal heterogeneity in individual pancreatic cancers and char-
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greater than 40% (Waddell et al., 2015), or have employed tech-
niques that purify tumor samples, either by generating cell lines
or patient-derived xenografts, or by using mechanical enrich-
ment techniques such as macrodissection or laser capture
microdissection (Jones et al., 2008; Witkiewicz et al., 2015).
Consequently, samples with low neoplastic cellularity have
been underrepresented in previous genome sequencing efforts,
even though low cellularity cancers comprise the majority of sur-
gically resected PDACs. Validated approaches for accurate
genomic profiling in tumors with low neoplastic cellularity, such
as those presented here, will be important for understanding
the biology of these carcinomas and will be increasingly neces-
sary for real-time genomic characterization of PDAC specimens
to guide clinical decision making.
RESULTS
Samples, Clinical Data, and Analytic Approach
Surgically resected primary infiltrating adenocarcinomas and
matched germline DNA from whole blood were identified from
150 patients with mostly stage I–III PDAC (four stage IV patients)
(Table S1). Detailed clinical and pathologic characteristics of the
cohort matched those of the general population of patients with
surgically resectable PDAC (He et al., 2014; Siegel et al., 2016)
(Table S1). Four patients with evidence of metastatic disease
(M1) at diagnosis were excluded from survival analyses. The me-
dian follow-up of the remaining 146 patients was 676 days, and
71 of these were alive at last follow-up. Among the clinical vari-
ables, only margin status (R0 versus R1) showed a significant in-
dependent correlation with overall survival (p = 0.007, q = 0.077).
The neoplastic cellularity (or tumor purity) ranged from 0% to
53% (median 18%) as judged by central pathology review (Table
S1). A single sample (IB-7644) was macrodissected to enrich for
neoplastic cellularity. Neoplastic cellularity was evaluated inde-
pendently by whole-exome sequencing using the ABSOLUTE al-
gorithm (STAR Methods) (Carter et al., 2012), and ranged from
9% to 89% (first quartile 20%; median 33%) (Table S1). Tumor
purity was also evaluated using DNA methylation, which pro-
duced estimates that were strongly correlated with ABSOLUTE
(R2 = 0.73, Table S1).
Landscape of Genomic Alterations
Recurrent Somatic Mutations
Whole-exome sequencing (WES; mean coverage 4053) identi-
fied somatic DNA alterations, including single nucleotide variants
(SNVs), small insertions and deletions (indels), and SCNAs. Sig-
nificant recurrent mutations were identified in KRAS, TP53,
CDKN2A, SMAD4, RNF43, ARID1A, TGFbR2, GNAS, RREB1,
and PBRM1 (Figures 1 and S1A). We also observed recurrent
mutations in several genes at false discovery rates (FDRs) above
our threshold of q = 0.1, including mutations in other known on-
cogenes, DNA damage repair genes, and chromatin modifica-
tion genes. Except forRREB1, these genes have been previously
reported as altered in PDAC (Bailey et al., 2016; Biankin et al.,
2012; Jones et al., 2008; Waddell et al., 2015; Witkiewicz et al.,
2015). Mutations in RREB1 included at least three predicted
loss-of-function variants (Figures 1 and S1A). RREB1 is activated
by the MAPK pathway, represses the miR-143/145 promoter,
and has been reported to be downregulated in PDAC (Costello186 Cancer Cell 32, 185–203, August 14, 2017et al., 2012; Franklin et al., 2014; Kent et al., 2010, 2013).
RREB1 is a positive regulator of the ZIP3 zinc transporter, and
thus recurrent mutations in RREB1 may suggest an important
role for zinc homeostasis in PDAC pathogenesis. Comparison
of missense mutations in our cohort of patients with those re-
ported in the literature using the Mutation Annotation and
Genome Interpretation (MAGI) tool (Leiserson et al., 2015) high-
lighted mutations in CTNBB1, PIK3CA, ERBB2, POLE, SF3B1,
and additional genes that have been identified in other cancer
types (Table S2).
To increase our power to detect somatic mutations in low-
purity samples, we pursued two additional sequencing strate-
gies. First, the KRAS codon 12, 13, and 61 hotspots were
sequenced using a microfluidic PCR-based approach with
very deep coverage (mean 30,0003). In addition, we de-
signed a targeted sequencing panel that encompassed signif-
icantly mutated genes identified by MutSigCV2 analysis within
the TCGA cohort, as well as a subset of additional genes
across functionally relevant classes that have been identified
as altered in pancreatic cancer by the International Cancer
Genome Consortium (Bailey et al., 2016) (Table S2). These tar-
geted genes were sequenced to higher coverage (6443)
compared with 4053 for WES. Through combined analysis
of both the WES and targeted sequencing data, we identified
many low-prevalence mutations in well-annotated genes that
may contribute to the pathogenesis of pancreatic cancer (Fig-
ure 1; Table S2). Several of these low-prevalence mutations
had potential therapeutically relevant implications (Figure S1B,
see below).
Germline Variants in Pancreatic Cancer
Susceptibility Genes
Approximately 5%–10%of PDAC occurs in patients with a family
history of the disease, and several genes have been identified for
which germlinemutations confer susceptibility to PDAC (Roberts
et al., 2016). We analyzed the matched germline exome
sequencing data for alterations in known germline predisposition
genes BRCA1, BRCA2, PALB2, STK11,CDKN2A, ATM, PRSS1,
MLH1, MSH2, MSH6, PMS2, EPCAM, and TP53. We observed
predicted pathogenic germline mutations in 8% of patients in
the cohort (11/149 non-hypermutated samples), including muta-
tions in BRCA2 (n = 6), ATM (n = 3), PALB2 (n = 1), and PRSS1
(n = 1) (Figure 1). Clinical records on these 11 patients were
not sufficient to fully evaluate for a family history of cancer. Eval-
uation of somatic mutation and copy number data on these sam-
ples with germline mutations revealed that the majority had loss
or mutation of the other allele, with only the PALB2 germline
mutant sample (IB-A5SP) and a single ATM mutant sample
(IB-AAUT) appearing to retain the wild-type allele. The missense
mutation observed in the PRSS1 cationic trypsinogen gene is
a known pathogenic activating mutation (R122H) that has been
associated with familial pancreatitis and a dramatically
increased (>503) risk of pancreatic cancer (Keim et al., 2001;
Whitcomb et al., 1996). Available TCGA clinical records for this
case (2J-AABA) suggested that this patient had a history of
chronic pancreatitis.
We observed significant enrichment for germline mutations in
the predisposition genes noted above in the ten KRAS wild-type
samples (p = 0.027, Fisher’s exact test of KRASwild-type versus
mutant).
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Figure 1. Landscape of Genomic Alterations in Pancreatic Ductal Adenocarcinoma
Integrated genomic data for 149 non-hypermutated samples (columns), including mutations (classified as truncating, in-frame or missense), high-level
amplifications and homozygous deletions (‘‘Deep Deletion’’), fusions derived from analysis of mRNA data, and germline mutations for selected genes
as described in the text. Overall number of mutations/Mb and clinicopathologic data for each sample are shown as tracks at the top. Significantly
mutated genes (q % 0.1) from exome sequencing data listed in order of q value, followed by other recurrently altered genes organized in functional
classes of oncogenes (red), DNA damage repair genes (green), and chromatin modification genes (blue). Significantly mutated genes from these
classes are also colored accordingly. The percentage of PDAC samples with an alteration of any type is noted at the left. See also Figure S1,
Tables S1, S2, and S3.Mutational Signatures
We investigated knownmutational signatures in the 150 samples
and found a single primary signature of C > T transitions at CpG
sites, which is associated with age of diagnosis (Alexandrov
et al., 2013) (Signature A, Figure S1C). In addition, one sample
with a mutation in the POLE polymerase demonstrated a hyper-
mutator signature (Signature B). Although we detected both so-
matic and germline BRCA1/2 and PALB2 mutations in our
cohort, we did not observe a mutational signature consistent
with BRCA1/2 deficiency, perhaps because relatively few sam-
ples (n = 7) had a mutation in one of these genes. In addition,
the single somatic mutations in BRCA1 and BRCA2 were
observed to have cancer cell fractions significantly less than
one, suggesting that these mutations were subclonal and thus
potentially less likely to exhibit a mutational signature of
BRCA1/2 deficiency in WES data from bulk tumor.Somatic Copy Number Aberrations
Arm-level somatic copy number aberrations were identified in
over a third of the tumors, using both SNP microarrays (whose
sensitivity was constrained by low tumor purity) andWES. These
included amplifications of 1q (33%) along with deletions of 6p
(41%), 6q (51%), 8p (28%), 9p (48%), 17p (64%), 17q (31%),
18p (32%), and 18q (71%) (Table S3), consistent with previous
studies (Bailey et al., 2016; Iacobuzio-Donahue et al., 2004;
Waddell et al., 2015). GISTIC analysis of focal amplifications
and deletions in the high-purity group revealed a number of
recurrent events containing known oncogenic drivers (Fig-
ure S1D; Table S3) (Mermel et al., 2011). These include amplifi-
cations of GATA6 (18q11.2), ERBB2 (17q12), KRAS (12p12.1),
AKT2 (19q13), and MYC (8q24.2), as well as deletions of
CDKN2A (9p21.3), SMAD4 (18q21.2), ARID1A (1p36.11), and
PTEN (10q23.31) (Figures 1 and S1D; Table S3).Cancer Cell 32, 185–203, August 14, 2017 187
Clinically Relevant Mutations
We assessed the clinical relevance of germline and somatic mu-
tations, fusions, and copy number alterations in a curated list of
genes (Figure S1B) using the PHIAL algorithm (Van Allen et al.,
2014). Ten percent of samples harbored germline or somaticmu-
tations in one of the DNA damage repair genes ATM, BRCA1,
BRCA2, and PALB2, potentially sensitizing these tumors to plat-
inum-based chemotherapy or poly-(ADP-ribose) polymerase
(PARP) inhibition (Sahin et al., 2016b). We observed low-preva-
lence alterations in several genes potentially amenable to other
targeted therapies, including mutations in BRAF, PIK3CA,
RNF43, STK11, and JAK1, as well as focal high-level amplifica-
tions in ERBB2. A single hypermutated sample harbored 19,957
mutations that included a mutation in POLE. This tumor may
have a higher neo-antigen load, which could have made the pa-
tient a candidate for immunotherapy approaches (Le et al.,
2015). Excluding common events in KRAS or CDKN2A, 42%
(63/150) of patients within this cohort had cancers with at least
one genomic alteration that could potentially confer eligibility
for current clinical trials, and 25% of the patients (38/150) had
cancers with two or more such events, suggesting a potential
basis for genotype-driven combination therapy trials.
Mutational Heterogeneity of KRAS Alterations in
Pancreatic Cancer
We evaluated the power to detect clonal and subclonal KRAS
mutations across a range of neoplastic cellularity (Figure S2).
We found that the combined depth of coverage across multiple
modalities used in this project enabled high-confidence detection
of KRAS mutations, including subclonal mutations that would
have been missed at lower sequencing depths. We observed
KRASmutations in 93% (140/150) of the samples. Multiple onco-
genicKRAS alleles were identified, including G12D (n = 62), G12V
(n = 41), and G12R (n = 28), as well as numerous other hotspot
codon 12 and 61 mutant alleles at a lower prevalence.
We used the ABSOLUTE algorithm for copy number and tumor
purity analysis to investigate mutational heterogeneity in detail,
using estimates of cancer cell fraction (CCF) for each mutation
(Carter et al., 2012). Evidence of multiple distinct KRAS muta-
tions was identified in five pancreatic cancers, including four
with multiple known oncogenic hotspot mutations (Figure 2). Ex-
amination of these samples with the ContEst algorithm (Cibulskis
et al., 2011) revealed very low probability of cross-individual
contamination as an explanation for this observation (data not
shown). We identified three examples of a clonal KRASmutation
concurrent with a subclonalKRASmutation at amuch lower CCF
(Figures 2A–2C), suggesting that in these samples, some of the
individual neoplastic cells harbored multiple KRAS mutations
(Figure 2D). In each of the samples with multiple KRAS muta-
tions, the individual mutations were observed on distinct
sequencing reads, confirming that thesemutations are occurring
on different alleles rather than the same allele (data not shown).
Notably, three of four cases with multiple hotspot KRAS muta-
tions contained a G12R mutation as the dominant clone (p =
0.025, Fisher’s exact test of G12R versus other hotspot codons
as double mutant). Another case hadmultiple mutations, each of
which was subclonal, and whose CCFs complemented each
other (Figure 2E), suggesting that these different KRAS muta-
tions occurred in separate neoplastic cells in a single tumor (Fig-
ure 2F). In contrast, when we analyzed publically available TCGA188 Cancer Cell 32, 185–203, August 14, 2017data from other tumor types sequenced at conventional
sequencing depths (80–1003), we found no other evidence
of multiple hotspot KRAS mutations within the same cancer
(data not shown).
Landscape of KRAS Wild-Type Samples
KRAS gene mutations were not identified in 10/150 samples,
despite deep sequencing with three different approaches. As
noted above, we observed an enrichment for germlinemutations
in familial risk genes within KRAS wild-type tumors. To identify
other possible molecular drivers in these cancers, we conducted
a thorough investigation of mutations, copy number alterations,
and translocation events in the RAS pathway, significantly
mutated genes, and other known cancer genes (Table S4) (Fig-
ure 3A). We found a GNAS mutation in three of ten KRAS wild-
type samples (Figures 3A and 3B), as well as a known
pathogenic activating mutation in JAK1 (R724H) (Flex et al.,
2008). Two KRAS wild-type tumors harbored a known onco-
genic missense mutation in CTNNB1 (Figure 3C).
In six of the ten samples, we identified somatic genetic alter-
ations that likely activate the RAS-MAPK pathway upstream or
downstream of KRAS (Figure 3A). Specifically, we discovered
two in-frame deletions in BRAF that have recently been shown
to activate the protein and drive MAPK signaling (Figure 3D)
(Chen et al., 2016; Foster et al., 2016). A CUX1-BRAF fusion
was identified in RNA-sequencing and WES data. We also
observed mutations in negative regulators of the RAS-MAPK
pathway, including NF1, SPRED1, and DUSP6. In a single sam-
ple, we observed a very focal high-level amplification of ERBB2
that encodes the HER2 receptor tyrosine kinase (Figure 3E).
Thus, RAS pathway activation is a prominent molecular driver
of pancreatic cancers, even when KRAS itself is not mutated.
Several of the alternative activators of the RAS pathway are
potentially targetable with existing therapies (Figure S1B).
We examined protein expression profiling with reverse-phase
protein arrays (RPPA) on the subset of tumors with higher
neoplastic cellularity (ABSOLUTE purity R33%), including five
of ten KRAS wild-type tumors (see the section on Protein
Expression). Despite small numbers of samples examined, the
KRAS wild-type tumors had significantly elevated TSC/MTOR
signaling pathway activity compared with the KRAS mutant
tumors (Figure 3F). Four of five KRAS wild-type tumors demon-
strated elevated levels of multiple phosphorylated effector pro-
teins in the MTOR signaling pathway, including phosphorylated
4EBP1 and S6K. Notably, the TSC/MTOR pathway score was
markedly elevated in the single sample (LB-A8F3-01A) for which
we did not identify another putative driver event through analysis
of WES data (Figure 3A, right-most column). Furthermore, the
only KRAS wild-type tumor that did not have an elevated TSC/
MTOR pathway score harbored an activating BRAF mutation,
and its pathway score tracked with those of KRAS mutant
samples (Figure 3F). These data suggest that functional activa-
tion of the MTOR signaling pathway may be an alternative onco-
genic driver in KRAS wild-type pancreatic cancer.
Tumor Purity Informed Analysis of Genome
Characterization Platforms
The low neoplastic cellularity of PDAC challenged analyses of
mRNA, long non-coding RNA (lncRNA), microRNA (miRNA),
Figure 2. KRAS Mutational Heterogeneity
(A–C) Histogram of cancer cell fraction (CCF) estimates (x axis) for all identified mutated genes (y axis, blue bars) as well as point estimates and 95% confidence
intervals for selected genes (colored horizontal lines) for a tumor (YB-A89D) with clonal KRASG12Rmutation and clonal CDKN2A and SMAD4mutations but also
harboring a second apparent subclone with a KRASG12D and TP53mutation (A), a tumor (XD-AAUG) with a clonal KRASG12Vmutation and a subclonal KRASQ61H
mutation (B), and a tumor (RB-A7B8) with a clonal KRASG12R mutation, a subclonal KRASG12V mutation, and a clonal GNAS mutation (C).
(D) Schematic model of the tumor shown in (C) based on CCF evidence for biallelic KRAS mutations in a subset of cells.
(E) Tumor (2J-AAB1) with CCF evidence of multiple subclonal KRAS alterations in the same tumor.
(F) Schematic model of the tumor shown in (E) with evidence for multiple subclones, each harboring a different KRAS mutation.
See also Figure S2.reverse-phase protein array (RPPA), and DNA methylation,
which were heavily confounded by tumor purity (Figures 4A
and S3A). Therefore, we used a two-step analysis strategy inwhich we split our cohort based on the median purity into a
‘‘high-purity’’ set of 76 samples with ABSOLUTE purity R33%
and a ‘‘low-purity’’ set of 74 samples that had ABSOLUTE purityCancer Cell 32, 185–203, August 14, 2017 189
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Figure 3. Alternate Drivers in KRASWild-Type Samples
(A) Co-mut plot for KRAS wild-type tumors (n = 10) displaying integrated data, including mutations, copy number alterations, mRNA fusions, and germline al-
terations as described in Figure 1.
(B–D) Recurrently mutated GNAS (B), CTNNB1 (C), and BRAF (D) observed in KRAS wild-type samples.
(legend continued on next page)
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<33%. We clustered high-purity samples using unsupervised
approaches, obtaining sets of genes/markers that were more
likely to reflect the biology of the neoplastic cells, rather than
that of the admixed stromal and other cells. We then used infor-
mation derived from these high-purity samples, e.g., discrimina-
tory features or trained Support Vector Machines, to classify
the remaining low-purity samples (Figure 4B). We found that
this approach mitigated the tendency of low-purity samples to
co-segregate, and allowed us to achieve clustering results
that were not significantly associated with purity, as dis-
cussed below.
mRNA Subtypes
Two large studies using either PDAC (Moffitt et al., 2015) or
PDAC and other types of pancreatic cancer samples (Bailey
et al., 2016) recently reported gene expression subtypes of
pancreatic cancer, extending the subtypes previously described
by Collisson et al. (2011). We applied the clustering techniques
from each of these studies to our data (Figures S3B–S3D), repro-
ducing the four-group classification (squamous, immunogenic,
pancreatic progenitor, or aberrantly differentiated exocrine
[ADEX]) of Bailey et al. (2016), the three-group classification
(classical, quasimesenchymal, or exocrine-like) of Collisson
et al. (2011), and the two-group classification (basal-like or clas-
sical) of Moffitt et al. (2015). We found that classification of sam-
ples as basal-like or classical (Bailey et al., 2016; Moffitt et al.,
2015) was independent of purity (Figure 4C). In contrast, the
classifications of Collisson et al. and Bailey et al. were correlated
with tumor purity in our cohort, with samples classified as
exocrine-like or quasimesenchymal (Figure 4D), or samples clas-
sified as ADEX or immunogenic (Figure 4E) having lower tumor
purity. We also found that, among low-purity tumors, a higher
estimated leukocyte fraction (Carter et al., 2012) was associated
with immunogenic samples (Figure 4F). Further, the ADEX class
was a subset of the exocrine-like class (Collisson et al., 2011)
(Figures 4F and S3E–S3G).
Considering only the high-purity samples in our cohort, the
squamous samples of Bailey et al. showed significant overlap
with the basal-like samples defined by Moffitt et al., while the
Bailey et al. pancreatic progenitor and Collisson et al. classical
group largely overlapped the classical samples defined by Mof-
fitt et al (Figures 4F and S3E–S3G). These observations suggest
that high-purity tumors can be consistently classified into a
basal-like/squamous group and a classical/progenitor group.
The strong association of immunogenic and ADEX or exocrine-
like subtypes with the low-purity samples in our cohort suggests
that these subtypes may reflect gene expression from non-
neoplastic cells.
Analysis of Genome Characterization Platforms
Following the schematic in Figure 4B, we identified de novo
PDAC subtypes from DNA methylation, copy number, lncRNA,
miRNA, and RPPA data. Using the non-coding RNA and RPPA(E) Focal high-level amplification of ERBB2 in a KRAS wild-type sample. Red do
ABSOLUTE copy number (CN) are indicated on the x and y axes, respectively. G
(F) RPPA scores for TSC/MTOR pathway in samples with KRAS mutation (blue),
scatterplots show mean with SD. Mann-Whitney rank-sum test, p = 0.0007.
See also Table S4data, all samples were classified into groups. In contrast, for
DNA methylation and copy number, some samples with
extremely low purity were not classified due to low signal inten-
sity. We investigated whether classification was more feasible in
higher-purity tumors by measuring how well individual samples
correlated to each cluster centroid (Figures S3H–S3J). For
example, in lncRNA clusters, as purity increased, the samples
classified into lncRNA group 1 became more similar to the
centroid of all samples in lncRNA group 1 and less similar to
the centroid of lncRNA group 2. This again demonstrates that
it is easier to classify tumors into molecularly similar groups
when the tumors have a high proportion of neoplastic cells.
DNA Methylation
Unsupervised clustering of DNA methylation data for the 76
high-purity samples revealed two major subgroups (H1 and
H2, Figure S3K). The H1 cluster (n = 41) had more extensive
DNA hypermethylation than the H2 cluster (n = 35). In the low-
purity sample set (n = 74), we identified three clusters (L1, L2,
and L3, Figure S3K). The prevalence and level of cancer-spe-
cific DNA hypermethylation were markedly lower in the samples
in the L1 cluster (n = 30), and the samples in this cluster also had
significantly lower neoplastic purity than did the other clusters
(p = 0.0087, median 15% versus 22%, 22% for clusters L2
and L3, respectively). Given this, we excluded the samples in
the L1 cluster from subsequent integrative analyses. DNA hy-
permethylation profiles in the lower-purity L2 and L3 clusters
were similar to the higher-purity H1 and H2 clusters, respec-
tively, even though the levels of DNA methylation were consis-
tently weaker across CpG sites in the lower-purity subgroups
(Figure S3K). For the integrative multi-platform analyses
described below, we merged the higher-purity H1 cluster and
lower-purity L2 cluster to create a DNA hypermethylation sub-
group 1 (n = 55), and we merged the higher-purity H2 cluster
and lower-purity L3 cluster to form a DNA hypermethylation
subgroup 2 (n = 65).
Integrated analysis of the DNAmethylation andmRNA expres-
sion data revealed 98 genes that were silenced by DNA methyl-
ation, including genes that have been implicated in the develop-
ment of other cancers but not previously reported to be altered in
pancreatic cancer (Table S5) (Nagpal et al., 2014). Notable genes
include ZFP82, which is epigenetically silenced and suspected
to function as a tumor suppressor (Xiao et al., 2014; Yu et al.,
2015; Fan et al., 2016); PARP6 hypermethylation (Honda et al.,
2016; Qi et al., 2016); DNAJC15, which is hypermethylated in a
number of tumor types (Ehrlich et al., 2002; Lindsey et al.,
2006) and whose inactivation has been associated with chemo-
therapeutic drug resistance in breast (Fernandez-Cabezudo
et al., 2016) and ovarian cancers (Rein et al., 2011). We also iden-
tified genes that were epigenetically silenced at low prevalence
throughmanual examination of the genes known to be important
in cancer, including BRCA1 and MGMT (each silenced in
one case).tted lines indicate the boundaries of the amplicon. Chromosome position and
enes positioned within the genomic locus are indicated below.
BRAF mutation (brown), or wild-type for both KRAS and BRAF (red). Column
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Figure 4. Assessment and Impact of Purity on Molecular Analysis
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See also Figure S3 and Table S5.
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Copy Number Clustering
Clustering of SCNAs in high-purity tumors produced two major
clusters, one with ‘‘high’’ and one with ‘‘low’’ levels of copy num-
ber alterations (Figure S3L, ‘‘High Purity’’). These two clusters
did not significantly differ in purity (Figures S3M and S3N). Using
a classifier generated from high-purity tumor clustering, we
grouped low-purity tumors into the same clusters (Figure S3L,
‘‘Low Purity’’). A smaller percentage of low-purity tumors were
classified as ‘‘high’’ copy number variation compared with
high-purity tumors (12% versus 37%, Fisher p < 0.001). In addi-
tion, 17 of the low-purity tumors (22%) as well of the one of the
high-purity tumors had few if any SCNAs, and were classified
as non-aneuploid.
Non-coding RNA
miRNA
For the 76 high-purity tumor samples, we used unsupervised
non-negative matrix factorization (NMF) consensus clustering
(Gaujoux and Seoighe, 2010) with the most-variant 25% (n =
303) of miRNA mature strands (miRs) to obtain three clusters
that were independent of purity (p = 0.14, Kruskal-Wallis test)
(Figure 5A, S4A, and S4B). Many of the miRs that were differen-
tially abundant across the clusters (Figure 5B, Table S6, Fig-
ure S4C) have been reported as prognostic, as differentially
abundant between non-neoplastic and neoplastic tissue, or as
functionally involved in signaling pathways in pancreatic cancer
(Frampton et al., 2015; Halkova et al., 2015; Hernandez and Lu-
cas, 2016; Lee et al., 2015; Lou et al., 2013; Sun et al., 2015). For
example, miR-21 has been reported to be prognostic in pancre-
atic cancer (Frampton et al., 2015), and to be more abundant in
tumors than in non-neoplastic pancreatic tissue (Halkova et al.,
2015; Hernandez and Lucas, 2016). We noted that RNF43muta-
tions were significantly enriched (p = 3.7 3 103, Fisher exact
test) in miR cluster 2 (Figure 5A). RNF43 mutations have thera-
peutic implications (Figure S1B) (Jiang et al., 2013; Koo et al.,
2015) and frequently occur in intraductal papillary mucinous
neoplasm (IPMN) precursor lesions (Amato et al., 2014; Wu
et al., 2011a), suggesting biologic and clinical relevance for
miR cluster 2.
lncRNA
We used poly(A)-selected RNA-sequencing data to calculate
transcript abundances for over 8,000 Ensembl v82 lncRNAs,
generating a comprehensive pancreatic lncRNA transcriptome.
For the 76 high-purity samples, unsupervised consensus clus-
tering (Wilkerson and Hayes, 2010), applied to expression pro-
files for a subset of 360 highly variant lncRNAs, identified two
clusters that were independent of purity (p = 0.66, Kruskal-
Wallis) and concordant (p = 7.6 3 109) with the basal-like
and classical mRNA subtypes (Figures 5C and S4D–S4H).
LncRNAs that were differentially expressed between the largely
basal-like cluster 1 and the largely classical cluster 2 (Figure 5D
and S4D) included cancer-associated UCA1 (Huang et al.,
2014; Li et al., 2016; Nie et al., 2016; Wang et al., 2008),
HNF1A-AS1 (Muller et al., 2015; Wu et al., 2015; Yang et al.,
2014), and NORAD (LINC00657) (Lee et al., 2016). We then
used these differentially expressed lncRNAs to cluster all 150
of our samples, and found a stable two-cluster solution that
was concordant with the classification derived from the high-
purity set alone (Figure S4H).The most highly differentially expressed lncRNA associated
with the classical mRNA subtype was EVADR, which has been
reported to be specifically and abundantly expressed in adeno-
carcinomas, including PDAC (Gibb et al., 2015). The lncRNA
DEANR1 (LINC00261) was nearly two-fold more abundant in
the classical subtype than in the basal-like subtype. This lncRNA
regulates FOXA2 expression by recruiting SMAD2/3 to the
FOXA2 promoter (Jiang et al., 2015). Intriguingly, DEANR1 has
been implicated as having functional roles in pancreatic cancer
(Muller et al., 2015) and in the formation of the pancreas (Jiang
et al., 2015; Zorn and Wells, 2009). Like DEANR1, the lncRNA
GATA6-AS1 was also more than 2-fold overexpressed in clas-
sical tumors; it has been shown to be transcriptionally activated
when embryonic stem cells (ESCs) differentiate into endoderm
(Sigova et al., 2013).
Unsupervised consensus clustering (Wilkerson and Hayes,
2010) within the 76 high-purity samples also identified a robust
five-cluster solution (Figures S4F, S4G, and S4I–S4K) that was
statistically independent of purity (p = 0.14, Kruskal-Wallis test)
and overall survival (log rank p = 0.73), and was strongly concor-
dant with the two-cluster solution (p = 1.5 31017), and with the
mRNA basal-like and classical subtypes of Moffitt et al. (p =
3.63109, Fisher exact test). Distributions of abundance for
certain lncRNAs varied between the largely basal-like clusters
1 and 2, and across the largely classical clusters 3–5 (Figures
S4J–S4K), suggesting that lncRNAs, like miRNAs, may have
differential effects within the classical and basal-like mRNA
subtypes.
Protein Expression
Unsupervised consensus clustering of protein expression
measured on a 192-antibody array for 45 of the 76 high-purity
samples identified four clusters (Figure 6A) that exhibited signif-
icant differences in survival (Figure 6B). We examined differ-
ences in pathway activity between clusters using nine pathway
activity scores (Akbani et al., 2014) (Table S7), identifying signif-
icantly different scores for epithelial-to-mesenchymal transition
(EMT), apoptosis, TSC/mTOR, cell_cycle, and RTK pathways
(Figure 6C). Tumors from cluster 3, which had better survival,
were characterized by low EMT and apoptosis pathway activity,
but high TSC/mTOR and RTK activity. The same approach
applied to the 39 low-purity samples did not show significant dif-
ferences in survival (p = 0.36, likelihood ratio test), suggesting, as
was observed with other platforms, that low purity adversely af-
fects the analysis.
Integrative Analysis
Cross-platform Clustering
We observed a high degree of overlap betweenmRNA basal-like
or classical subtypes and groupings produced by miRNA (p =
1.0 3 104), copy number (p = 0.014), lncRNA (p = 3.6 3
109), TP53 mutation status (83% versus 64%, p = 0.01), and
GNAS mutation status (p = 0.11) (Figure S5A). Due to the strong
concordance among these data types, cluster of clusters anal-
ysis (Cancer Genome Atlas Network, 2012) favored a two-cluster
solution driven by either lncRNA or mRNA (Figure S5B).
To integrate information from multiple platforms, we per-
formed Similarity Network Fusion (SNF), which has been shown
to produce homogeneous, clinically relevant subtypes inmultipleCancer Cell 32, 185–203, August 14, 2017 193
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TCGA studies (Wang et al., 2014). We applied SNF to the high-
purity cohort using sample-to-sample similarities derived from
mRNA, miRNA, and DNA methylation. We found a two-cluster
solution that was independent (p = 0.79) of tumor purity and a
three-cluster (plus one outlier) solution that was associated
(p = 0.025) with tumor purity. Pathology review showed that
the outlier sample (US-A776) contained only a small component
of invasive cancer with most of the sample being non-invasive
IPMN. The clusters defined by SNF were highly concordant
with results obtained from miRNA, lncRNA, or mRNA alone (Fig-
ures 7A, 7B, S5C, and S5D).
Activation and Inactivation of Genes by Multiple
Genomic Aberrations
We found that GATA6 and CDKN2A were altered by multiple
mechanisms. In an integrated analysis of DNA methylation,
copy number, and RNA expression, we found that GATA6
mRNA and an antisense lncRNA, GATA6-AS1, appeared to be
deregulated by two distinct mechanisms (Figure 7C). Basal-like
tumors exhibited higher DNAmethylation nearGATA6 and lower
expression of both GATA6 and GATA6-AS1 mRNA; in contrast,
classical tumors showed copy number gains of the GATA6
neighborhood, as well as higher expression of GATA6 and
GATA6-AS1 mRNA. These results are consistent with previous
reports of GATA6 amplification and elevated GATA6 mRNA
expression in the classical subtype of PDAC (Collisson et al.,
2011; Fu et al., 2008), as well as previous reports of GATA6
loss in basal-like tumors with poor outcome (Martinelli et al.,
2016). Thus, there appears to be a subtype-associated positive
or negative selective pressure on theGATA6 genomic neighbor-
hood, confirming an important and complex role for GATA6 and
possibly GATA6-AS1 in PDAC.
Cross-platform examination suggested that CDKN2A is
downregulated through multiple mechanisms (by DNA methyl-
ation in six samples, by deletions in 34, and by intragenic muta-
tion in 26) (Figure 7D and Table S1). A disproportionate number
of samples with CDKN2A alterations were identified in the high
neoplastic cellularity group (alterations in 42/76 high-purity
versus 23/74 low-purity, p = 0.003). These findings further under-
score how low neoplastic cellularity may obscure genetic
alterations.
RNA Networks
To identify mechanisms of gene regulation in PDAC that may be
contributing to the subtypes described above, we assessed cor-
relations between DNA methylation, miRNAs, mRNAs, and
lncRNAs that were consistent with targeting and regulatory rela-
tionships. In the high-purity samples, we identified a network of
correlations (Figure 7E) consistent with a basal-like/classical
subtype model of PDAC (Figures S5E–S5K; Table S8). The
network included many genes that were overexpressed in
basal-like tumors and that we predicted were regulated by
miR-192-5p and miR-194-5p; In contrast to their overexpressed
mRNA targets, thesemiRswere underexpressed in basal-like tu-
mors compared with classical tumors. The nomenclature
‘‘basal-like’’ reflects similarities with basal breast and bladder(C and D) Results of a two-cluster consensus clustering solution (Wilkerson and
shown in (A) and (B), respectively. All boxplots shown displaymedian values and th
range. FPKM, fragments per kilobase of transcript per million mapped reads. All
See also Figure S4 and Table S6.cancers (Moffitt et al., 2015), and, for the genes in this correlation
network, gene set analysis confirmed enrichment of genes from
both ‘‘up in basal BRCA’’ and ‘‘down in luminal BRCA’’ sets
(adjusted p = 5.23 1055, 2.23 1070) (Figure 7E). In high-purity
tumors, the network included an anti-correlation between
miR-192-5p expression and DNA hypermethylation at probe
cg02258444, suggesting that miR-192-5p expression, which is
high in classical tumors, may be suppressed by DNAmethylation
in basal-like tumors (Figure 7F). In addition, the network included
anti-correlations between expression of miR-194-5p and miR-
192-5p and expression of CAV1, consistent with predicted
(Agarwal et al., 2015; Miranda et al., 2006) and experimentally
validated miR-mRNA interactions (Chou et al., 2016a). CAV1
has been implicated in several PDAC phenotypes (Chatterjee
et al., 2015) (Figure 7F). Taken together, these data suggest
that regulation of a number of miRNAs by DNA methylation
may contribute to the mRNA subtypes in PDAC.
DISCUSSION
We present a multi-platform molecular analysis of 150 PDAC
specimens that exhibit a range of neoplastic cellularity represen-
tative of the clinico-pathologic spectrum of this disease. We
demonstrated that the depth of sequencing is critical to the
detection of mutations and SCNAs in low cellularity tumors,
emphasizing the need for very deep sequencing of low-purity
samples to enable sufficient power to detect both clonal and
subclonal alterations. Our analysis also highlights the impor-
tance of considering neoplastic cellularity when analyzing other
molecular characterization platforms and using these to stratify
samples.
We confirmed multiple previously identified driver genes in
PDAC, and we identified an additional driver gene, RREB1.
Excluding mutations in KRAS, 42% of the patients had a cancer
that harbored at least one alteration that could inform enrollment
in current genotype-directed clinical trials. Germline and somatic
mutations in the DNA damage repair genes BRCA2, PALB2, and
ATM were observed in 8% of samples, representing a class of
patients for whom platinum-based chemotherapy and/or PARP
inhibition may have therapeutic benefit. Importantly, these data
highlight the potential value of clinical testing for these germline
variants even in the absence of a clear cancer family history
(Goggins et al., 1996; Grant et al., 2015).
Deep sequencing of KRAS enabled a high-confidence esti-
mate that 93% of PDACs have KRAS mutation. A thorough
investigation of other potential driver events in the KRAS wild-
type tumors indicated that 60% of them harbor alternative
RAS-MAPK pathway-activating alterations, further highlighting
the importance of this pathway in this disease.We observed clin-
ically relevant alterations with important therapeutic potential in
six of the ten KRAS wild-type tumors. Moreover, in a subset of
these ten KRAS wild-type tumors, we observed elevated levels
of phosphorylation of MTOR pathway proteins, suggesting
that the MTOR pathway may be a therapeutic target in KRASHayes, 2010) for a subset of highly variant lncRNAs presented similar to that
e 25th to 75th percentile, while whiskers extend up to 1.5 times the interquartile
data points are shown as individual dots.
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Figure 6. RPPA Profiles Identify Biologically Distinct Subsets of High Purity Tumors
(A) Unsupervised consensus clustering of RPPA protein expression data for 45 of the 76 high-purity samples.
(B) Cox survival analysis between clusters (p = 0.045, likelihood ratio test from Cox analysis with purity as covariate).
(C) Differences in proteomic pathway activity scores across RPPA cluster/class for several pathway scores defined in Akbani et al. (2014). Boxplots indicate the
median and upper and lower quartiles, with whiskers extending 1.5 times the interquartile range. Points indicate pathway scores for all 45 samples.
See also Table S7.wild-type pancreatic cancers. These data support deep molec-
ular profiling of KRAS wild-type tumors to identify drivers with
potential therapeutic importance.
We also identified evidence for KRAS mutational heterogene-
ity that complicates our understanding of the role of KRAS in the
progression of pancreatic cancer. Multiple KRAS mutations,
including subclonal mutations, were identified in a small number
of the specimens, including cases with apparent subclonal bial-
lelic KRASmutations. While the existence of multiple KRASmu-
tations has been previously reported in non-invasive IPMNs
(Izawa et al., 2001; Tan et al., 2015; Wu et al., 2011b), we report
multiple KRAS mutations occurring in invasive PDAC. The iden-
tification of multiple subclonal KRAS mutations may represent196 Cancer Cell 32, 185–203, August 14, 2017the convergent evolution of multiple clones of advanced cancer
with independent KRAS mutations. In addition, the apparent
occurrence of multiple KRAS mutations within individual
neoplastic cells suggests an additional selective advantage to
development of a second KRAS mutation, perhaps from
enhanced KRAS signaling in these cells. This observation com-
plements other evidence that multiple RAS pathway lesions
may occur in the same cancer cells to promote tumor progres-
sion, such as through amplification of themutant allele or co-mu-
tation of negative regulators of the pathway (Lock and Cichow-
ski, 2015). Although the number of cancers with multiple KRAS
mutations is small, the KRASG12R allele is enriched in these sam-
ples, suggesting that this allele may have distinct signaling
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properties that encourage selection for additional intratumoral
KRASmutations during tumor progression. Further experimental
validation of this hypothesis is required. As therapeutic discovery
efforts progress toward development of allele-specific small-
molecule inhibitors of the KRAS protein (Lito et al., 2016; Ostrem
et al., 2013), the finding of multiple oncogenic KRASmutations in
the same sample may have important clinical ramifications,
including the increased propensity for emergence of therapeutic
resistance in these cancers.
Previous analyses of gene expression have identified mRNA
subtypes of pancreatic cancer (Bailey et al., 2016; Collisson
et al., 2011; Moffitt et al., 2015). Taking advantage of molecular
purity estimates using the ABSOLUTE algorithm, we confirmed
two tumor-specific subtypes of pancreatic ductal adenocarci-
noma—basal-like/squamous and classical/pancreatic progeni-
tor—and corroborated these across platforms. We found that
GNAS mutations were enriched in classical subtype tumors,
whereas TP53 mutations were more prevalent in basal-like sub-
type tumors. These two subtypes were also distinguished by dif-
ferential regulation of gene expression via miRNA and DNA
methylation. We found that the previously reported immuno-
genic and ADEX subtypes (Bailey et al., 2016) were associated
with low neoplastic cellularity in our cohort. It is not clear from
our data whether the identification of these two subtypes is
driven by gene expression from the surrounding non-neoplastic
tumor microenvironment or from other types of pancreatic can-
cer that were not included in our cohort. Further experimental
characterization of these subtypes using single-cell profiling
technologies is encouraged.
Examining protein expression in high-purity samples revealed
prognostic subtypes, including a group of tumors with improved
overall prognosis and elevated RTK and MTOR signaling that
may suggest therapeutic opportunity. Integrated platform ana-
lyses that also considered cellularity revealed non-coding RNA
associations with tumor-specific subtypes. While biogenesis
similarities for coding mRNAs and many lncRNAs (Quinn and
Chang, 2016) suggest that subtypes identified from the two
data types should be largely concordant, lncRNA expression
can be specific for cell type and disease state (Mele et al.,
2017; Nguyen and Carninci, 2016), and functionally character-
ized lncRNAs can be specifically dysregulated in cancers
(Huarte, 2015; Quinn and Chang, 2016). Differential expression
of the EVADR, DEANR1, and GATA6-AS1 lncRNAs was associ-
ated with the classical (or pancreatic progenitor) molecular sub-
type of pancreatic cancer. EVADR was recently found to be
associated with stomach, lung, colorectal, gastric, and pancre-
atic adenocarcinomas (Gibb et al., 2015), while DEANR1 andFigure 7. Integrated Analysis
(A) Integrated clustering of methylation, miRNA, lncRNA, and mRNA data using S
(B) Network fusion diagram of the two integrated clusters: each node is a samp
ABSOLUTE purity. Edges are colored according to the datatype giving the stronge
clusters generally have lower purity, reflecting the weaker signal for molecular cl
(C) DNA methylation heatmap and overlapping tracks sorted by GATA6 express
(D) CDKN2A status in all 150 cases showing mutation, deletion, or methylation in
(E) Network of selected relationships between miRNA, lncRNA, mRNA, and met
nificant anti-correlations. Validated and predicted miRNA:mRNA associations fro
(F) Relationship of the expression of mir-192-5p with nearby DNA methylation a
display full range, median, and upper and lower quartiles.
See also Figure S5 and Table S8.
198 Cancer Cell 32, 185–203, August 14, 2017GATA6-AS1 have been found to be associated with differentia-
tion (Jiang et al., 2015). Our results suggest a potentially impor-
tant relationship between non-coding RNAs and differentiation
genes, including GATA6, that have previously been associated
with classical/progenitor subtype tumors (Bailey et al., 2016;
Collisson et al., 2011; Moffitt et al., 2015), as well as potentially
new relationships between non-coding RNA and the more
aggressive basal-like/squamous subtype tumors (Bailey et al.,
2016; Moffitt et al., 2015).
Our integrated analysis across multiple molecular profiling
platforms reveals a complex molecular landscape of PDAC
and provides a roadmap for precision medicine.STAR+METHODS
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STAR+METHODSKEY RESOURCES TABLEREAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
RPPA antibodies RPPA Core Facility, MD Anderson Cancer
Center; Tibes et al., 2006
See Table S7
Biological Samples
Primary tumour samples Multiple tissue source sites, processed
through the Biospecimen Core Resource
See Methods: Experimental Model and
Subject Details
Critical Commercial Assays
SeqCap EZ Human Exome Library v3.0 Roche Sequencing Catalog: 06465692001
Genome-Wide Human SNP Array 6.0 ThermoFisher Scientific Catalog: 901153
Infinium HumanMethylation450
BeadChip Kit
Illumina Catalog: WG-314-1002
EZ-96 DNA Methylation Kit Zymo Research Catalog: D5004
AmpFLSTR Identifiler PCR amplification kit ThermoFisher Scientific Catalog: 4322288
Illumina Barcoded Paired-End Library
Preparation Kit
Illumina https://www.illumina.com/techniques/
sequencing/ngs-library-prep.html
TruSeq RNA Library Prep Kit Illumina Catalog: RS-122-2001
TruSeq PE Cluster Generation Kit Illumina Catalog: PE-401-3001
Phusion High-Fidelity PCR Master Mix
with HF Buffer
New England Biolabs Catalog: M0531L
VECTASTAIN Elite ABC HRP Kit
(Peroxidase, Standard)
Vector Lab Catalog: PK-6100
Deposited Data
Raw and processed clinical, array and
sequence data.
Genomic Data Commons https://gdc.cancer.gov/legacy-archive/
Digital pathology images Genomic Data Commons
Cancer Digital Slide Archive
https://gdc-portal.nci.nih.gov/legacy-
archive/
http://cancer.digitalslidearchive.net/
Oligonucleotides
NimblegenSeqCAp EZ custom capture
oligos
Roche Sequencing
120-mer IDT probes targeting TERT
promoter mutation hotspots
Integrated DNA Technologies
120-mer IDT probes targeting cancer-
related viruses
Integrated DNA Technologies
Software and Algorithms
ABSOLUTE Carter et al., 2012 http://archive.broadinstitute.org/cancer/
cga/absolute
Array-Pro Analyzer Media Cybernetics
Birdseed Korn et al., 2008 http://archive.broadinstitute.org/mpg/
birdsuite/birdseed.html
BWA (v0.5.9) Li and Durbin, 2010 http://bio-bwa.sourceforge.net/
CASAVA Illumina http://assets.illumina.com/content/
illumina-support/us/en/sequencing/
sequencing_software/casava.html
ConsensusClusterPlus (v1.24.0) Wilkerson and Hayes, 2010 http://bioconductor.org/packages/release/
bioc/html/ConsensusClusterPlus.html
ContEst Cibulskis et al., 2011 http://archive.broadinstitute.org/cancer/
cga/contest
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Cufflinks (v2.2.1) Trapnell et al., 2010 https://cole-trapnell-lab.github.io/cufflinks/
EGC.tools (v1.4.11) NA https://github.com/uscepigenomecenter/
EGC.tools
EIGENSTRAT smartpca Price et al., 2006
Li and Yu, 2008
https://github.com/DReichLab/EIG
Genome Analysis Toolkit (GATK),
HaplotypeCaller (v3.6)
McKenna et al., 2010 https://software.broadinstitute.org/gatk/
GISTIC2 (v2.0.22) Mermel et al., 2011 http://archive.broadinstitute.org/cancer/
cga/gistic
iCluster Shen et al., 2012 https://www.mskcc.org/departments/
epidemiology-biostatistics/biostatistics/
icluster
iCoMut NA http://firebrowse.org/iCoMut/
Indelocator NA https://www.broadinstitute.org/cancer/
cga/indelocator
In Silico Admixture Removal (ISAR) Zack et al., 2013
Integrative Genomics Viewer (IGV) Thorvaldsdottir et al., 2013 http://software.broadinstitute.org/
software/igv/
KING Manichaikul et al., 2010 http://people.virginia.edu/wc9c/KING
MAGI Leiserson et al., 2015 http://magi.brown.edu
MapSplice (v0.7.4) Wang et al., 2010 http://www.netlab.uky.edu/p/bioinfo/
MapSplice/
methylumi (v2.10.0) NA https://www.bioconductor.org/packages/
release/bioc/html/methylumi.html
MicroVigene VigeneTech http://www.vigenetech.com/
MicroVigene.htm
MuTect Cibulskis et al., 2013 http://archive.broadinstitute.org/cancer/
cga/mutect
MutSig2CV Lawrence et al., 2014 http://archive.broadinstitute.org/cancer/
cga/mutsig
NMF (v0.20.5) Gaujoux and Seoighe, 2010 https://cran.r-project.org/web/packages/
NMF/
Oncotator Ramos et al., 2015 http://archive.broadinstitute.org/cancer/
cga/oncotator
Picard pipeline (v1.46) NA https://broadinstitute.github.io/picard/
pheatmap (v0.7.7, v1.0.2) NA https://cran.r-project.org/web/packages/
pheatmap/
Python 2.7, SciPy, NumPy NA https://www.scipy.org/
RSEM Li and Dewey, 2011 https://deweylab.github.io/RSEM/
samr (v2.0) Li and Tibshirani, 2013 https://cran.r-project.org/web/packages/
samr
SAM Tusher et al., 2001 http://statweb.stanford.edu/tibs/SAM/
Samtools Li et al., 2009 http://samtools.sourceforge.net/
Similarity Network Fusion (SNF) Wang et al., 2014 http://compbio.cs.toronto.edu/SNF/SNF/
Software.html
STAR (v2.4.2a) Dobin et al., 2013 https://github.com/alexdobin/STAR
STAR-Fusion, Firehose version https://github.com/STAR-Fusion
Strelka (v0.4.6.2, v1.0.6) Saunders et al., 2012 https://sites.google.com/site/
strelkasomaticvariantcaller/
SuperCurve, SuperCurveGUI Hu et al., 2007; Zhang et al., 2009; Ju
et al., 2015
http://bioinformatics.mdanderson.org/
Software/supercurve/
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VarScan (v2.2.6) Koboldt et al., 2012
Variant effect predictor
(VEP) with LOFTEE plugin
McLaren et al., 2016, http://www.ensembl.org/info/docs/tools/
vep/index.html
https://github.com/konradjk/loftee
Other
Firehose, FireBrowse The Broad Institute https://gdac.broadinstitute.org/
http://firebrowse.org/
miRCode (v11) Jeggari et al., 2012 http://mircode.org/
NPInter (v3.0) Hao et al., 2016 http://www.bioinfo.org/NPInter/
Rna22 Miranda et al., 2006 https://cm.jefferson.edu/rna22/
TargetScan v7 Agarwal et al., 2015 http://www.targetscan.org/vert_71/CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact Benjamin
Raphael (braphael@princeton.edu).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Tumor and normal whole blood samples were obtained frompatients at contributing centers with informed consent according to their
local Institutional Review Boards (IRB, see below). Biospecimens were centrally processed and DNA, RNA, and protein were distrib-
uted to TCGA analysis centers. In total, 150 evaluable primary tumors with associated clinicopathologic data were assayed on at
least one molecular-profiling platform.
TCGA Project Management has collected necessary human subjects’ documentation to ensure the project complies with 45-CFR-
46 (the ‘‘Common Rule’’). The program has obtained documentation from every contributing clinical site to verify that IRB approval
has been obtained to participate in TCGA. Such documented approval may include one or more of the following:
d An IRB-approved protocol with Informed Consent specific to TCGA or a substantially similar program. In the latter case, if the
protocol was not TCGA-specific, the clinical site PI provided a further finding from the IRB that the already-approved protocol is
sufficient to participate in TCGA.
d A TCGA-specific IRB waiver has been granted.
d A TCGA-specific letter that the IRB considers one of the exemptions in 45-CFR-46 applicable. The two most common exemp-
tions cited were that the research falls under 46.102(f)(2) or 46.101(b)(4). Both exempt requirements for informed consent,
because the received data and material do not contain directly identifiable private information.
d A TCGA-specific letter that the IRB does not consider the use of these data and materials to be human subjects research. This
was most common for collections in which the donors were deceased.METHOD DETAILS
Sample Processing
DNA and RNA were extracted and quality was assessed at the central BCR. RNA and DNA were extracted from tumor and adja-
cent non-tumor tissue specimens using a modification of the DNA/RNA AllPrep kit (Qiagen). The flow-through from the Qiagen
DNA column was processed using a mirVana miRNA Isolation Kit (Ambion). This latter step generated RNA preparations that
included RNA < 200 nt suitable for miRNA analysis. DNA was extracted from blood using the QiaAmp DNA Blood Midi kit
(Qiagen).
RNA samples were quantified by measuring Abs260 with a UV spectrophotometer and DNA quantified by PicoGreen assay.
DNA specimens were resolved by 1% agarose gel electrophoresis to confirm high molecular weight fragments. A custom Se-
quenom SNP panel or the AmpFISTR Identifiler (Applied Biosystems) was utilized to verify that tumor DNA and germline DNA
representing a case were derived from the same patient. Five hundred nanograms of each tumor and germline DNA were sent
to Qiagen (Hilden, Germany) for REPLI-g whole genome amplification using a 100 mg reaction scale. RNA was analyzed via the
RNA6000 Nano assay (Agilent) for determination of an RNA Integrity Number (RIN), and only analytes with a RIN R 7.0 were
included in this study. Only cases yielding a minimum of 6.9 mg of tumor DNA, 5.15 mg RNA, and 4.9 mg of germline DNA
were included in this study.e3 Cancer Cell 32, 185–203.e1–e13, August 14, 2017
Sample Qualification
The BCR received tumor samples with germline controls from a total of 410 cases, of which 185 cases qualified and were sent for
further genomic analysis. Of the 225 that failed to qualify, 25 cases were disqualified prior to processing, 16 failed for pathology
screening, 175 cases failed due to molecular criteria, and 9 failed due to a genotype mismatch between tumor and germline.
Of the 16 that failed pathologic criteria, 12 failed for absence of tumor cells, 1 failed for necrosis, and 3 failed due to contaminating
tumor in the germline control sample. The majority of the 175 cases that failed molecular screening had RNA integrity scores of < 7.0
(143 cases). The remaining 32 cases had insufficient DNA and/or RNA yields for molecular characterization.
Samples with residual tumor tissue following extraction of nucleic acids were considered for proteomics analysis. When available,
a 10 to 20mg piece of snap-frozen tumor adjacent to the piece used formolecular sequencing and characterization was submitted to
MD Anderson for reverse phase protein array (RPPA analysis).
Microsatellite Instability Assay
Microsatellite instability (MSI) in qualified caseswas evaluated by the BiospecimenCore Resource at Nationwide Children’s Hospital.
MSI-Mono-Dinucleotide Assay was performed to test a panel of four mononucleotide repeat loci (polyadenine tracts BAT25, BAT26,
BAT40, & transforming growth factor receptor type II) & three dinucleotide repeat loci (CA repeats in D2S123, D5S346, & D17S250).
Two additional pentanucleotide loci (Penta D&Penta E) were included in this assay to evaluate sample identity. Multiplex fluorescent-
labeled PCR & capillary electrophoresis was used to identify MSI if a variation in the number of microsatellite repeats was detected
between tumor and matched non-neoplastic tissue or mononuclear blood cells. Equivocal or failed markers were re-evaluated by
singleplex PCR. Tumor DNA was classified as microsatellite-stable (MSS) if zero markers were altered, low-level MSI (MSI-L) if
less than 40% of markers were altered and high-level MSI (MSI-H) if greater than 40% of markers were altered. In the MSI-Mono-
Dinucleotide Assay, this classification equated to MSI-L if one or two markers were altered, and MSI-H if three to seven markers
were altered.
Individual markers were assigned a value of 1 through 6 based on the presence or absence of a MSI shift, allele homo/heterozy-
gosity and loss of heterozygosity (LOH) if relevant. Markers that demonstrated MSI shift were classified as follows; 1 = homozygous
alleles, 2 = heterozygous alleles with LOH and 3 = heterozygous alleles without LOH. Markers that did not demonstrate a MSI shift
were classified as follows; 4 = homozygous alleles, 5 = heterozygous alleles with LOH, and 6 = heterozygous alleles without LOH.
Penta D and E markers were scored in the same manner as the MSI markers; however, they did not contribute to MSI class
calculation.
Analytical Approach
Samples weremacrodissected to enrich for tumor purity, and characterized samples had post-dissection histologic neoplastic cellu-
larity ranging from 0-53% (median 18%) as judged by central pathology review (Table S1). Tumor purity was independently evaluated
in whole exome sequencing data on the 150 cancers that had histologically observable tumor using the ABSOLUTE algorithm (Carter
et al., 2012) and ranged from 9-89%, with a first quartile of 20% and a median of 33% (Table S1). The 9 samples that were found to
have < 1% neoplastic cellularity during central pathology review were held out from the tumor cohort. DNA, RNA and protein were
extracted from the specimens using standard TCGA approaches. One casewith high neoplastic cellularity (89%by ABSOLUTE) con-
tained a large precursor lesion in addition to an invasive carcinoma, explaining the discordance with the histologic assessment of
neoplastic cellularity, which included only an evaluation of the invasive component.
Purity Estimation and Two-Stage Clustering
Using our two-stage clustering strategy 18 samples were called non-aneuploid due to undetectable SCNA events (mean purity of
16%), and 30 samples had too little DNA methylation to be classified as either of the two subtypes (mean purity of 17%). Using
the mode of DNA methylation at hypermethylated sites as an indicator of purity resulted in an estimate that correlated well with
ABSOLUTE (R2 = 0.73), suggesting a low level of DNA methylation activity in stroma compared to neoplastic cells.
Whole Exome Sequencing (WES)
Sample Preparation and Sequencing
Starting with 250 ng input DNA, samples are quantified using a PicoGreen assay and diluted to a working stock volume and
concentration (2 ng/mL in 50 mL), then libraries are constructed and sequenced on Illumina HiSeq instruments with the use of
76-bp paired-end reads. Output from Illumina software is processed by the Picard data-processing pipeline to yield BAM files con-
taining well-calibrated, aligned reads. All process steps are performed using automated liquid handling instruments, and all sample
information tracking is performed by automated LIMS messaging.
Libraries are then constructed using the protocol described in Fisher et al. (Fisher et al., 2011) with several modifications. First,
initial genomic DNA input into shearing has been reduced from 3 mg to 100 ng in 50 mL of solution. Second, for adapter ligation, Illu-
mina paired end adapters have been replaced with palindromic forked adapters with unique 8 base index sequences embedded
within the adapter. These index sequences enable pooling of libraries prior to sequencing. Third, custom sample preparation kits
from Kapa Biosciences are now used for all enzymatic steps of the library construction process. For the majority of samples multiple
libraries were generated in order to achieve sequencing depths necessary for downstream analysis.Cancer Cell 32, 185–203.e1–e13, August 14, 2017 e4
In-solution hybrid selection was performed as previously described (Fisher et al., 2011). Following sample preparation, libraries are
quantified using PicoGreen. Based on PicoGreen quantification, libraries are normalized to equal concentration and pooled by equal
volume. Library pools are then quantified using a Sybr Green-based qPCRassay, with PCRprimers complementary to the ends of the
adapters (kit purchased from Kapa Biosciences). After qPCR quantification, library pools are normalized to 2 nM, denatured using
0.2 N NaOH, and diluted to 20 pM, the working concentration for downstream cluster amplification and sequencing. Denatured
library pools are spread across the number of sequencing lanes required to achieve target coverage for all samples.
Cluster amplification and sequencing of denatured templates are performed according to the manufacturer’s protocol (Illumina)
using HiSeq instruments. Read length is 76bp paired end reads, with additional cycles added to read molecular index sequences,
are performed. Output from Illumina software is processed by the Picard data-processing pipeline to yield BAM files containing
well-calibrated, aligned reads.
Mutation Analysis
Sequencing Data-Processing Pipeline (‘‘Picard Pipeline’’):
The ‘‘Picard’’ pipeline (http://picard.sourceforge.net/) generates a BAM file (http://samtools.sourceforge.net/SAM1.pdf) for each
sample andwas developed by the Sequencing Platform at the Broad Institute. Picard pipeline aggregates data frommultiple libraries
and flow cell runs into a single BAM file for a given sample. This file contains reads aligned to the human genome with quality scores
recalibrated using the Table Recalibation tool from the Genome Analysis Toolkit. Reads were aligned to the Human Genome Refer-
ence Consortium build 38 (GRCh38) using BWA v0.5.9 (Li and Durbin, 2010) (http://bio-bwa.sourceforge.net/). Unaligned reads that
passed the Illumina quality filter (PF reads) were also stored in the BAM file. Duplicate reads were marked such that only unique
sequenced DNA fragments were used in subsequent analysis. Sequence reads corresponding to genomic regions that may harbor
small insertions or deletions (indels) were jointly realigned to improve detection of indels and to decrease the number of false positive
single nucleotide variations caused by misaligned reads, particularly at the 3’ end. To improve the efficiency of this step, we per-
formed a joint local-realignment of all samples from the same individual (‘‘co-cleaning’’). All sites potentially harboring small insertions
or deletions in either the tumor or thematched normal were realigned in all samples. Finally, the Picard pipeline provided summaryQC
metrics such as the target coverage and an estimated level of ‘‘oxo-G’’ artifacts (Costello et al., 2013) for each BAM that were used in
subsequent processing.
Cancer Genome Analysis Pipeline (‘‘Firehose’’)
The Firehose pipeline (http://www.broadinstitute.org/cancer/cga/Firehose) performed additional QC on the bams, mutation calling,
small insertion and deletion identification, rearrangement detection, coverage calculations, annotation of detected mutations,
filtering for OxoG artifacts and filtering by ‘‘panel-of-normals’’ and by Exome Aggregation Consortium (ExAC) dataset. The pipeline
is an extensive series of tools for analyzing massively parallel sequencing data for both tumor DNA samples and their patient-
matched normal DNA samples. The pipeline contains the following steps:
1. Quality control on BAM files: The sample cross-individual contamination levels were estimated using the ContEst program
(Cibulskis et al., 2011).
2. Somatic point mutation calling: TheMuTect algorithm (Cibulskis et al., 2013) was used to detect somatic single nucleotide var-
iants (SNVs). SNVs were detected using a statistical analysis of the bases and qualities in the tumor and normal BAMs.
3. Small insertion and deletion detection: The Indelocator algorithm (https://www.broadinstitute.org/cancer/cga/indelocator)
was used to detect small insertions and deletions (InDels).
4. SNVs and InDel annotations: SNVs and InDels detected by MuTect and Indelocator, respectively, were annotated using On-
cotator (Ramos et al., 2015). Oncotator mapped somatic mutations to respective genes, transcripts, and other relevant fea-
tures. These annotations correspond to the fields in the TCGA Mutation Annotation Format (MAF) files version 2.4 (https://
wiki.nci.nih.gov/display/TCGA/Mutation+Annotation+Format+(MAF)+Specification).
5. Filtering for OxoG artifacts: 464 G>T/C>A transversions that are a consequence of heating, shearing, and oxidative damage to
the DNA during genomic library preparation (Costello et al., 2013) were filtered out of the call set. These 464 transversions were
found in the tumor sample BAM files of the following individuals: HZ-A77Q, IB-A7LX, IB-A7M4, S4-A8RP, XN-A8T3, YB-A89D
and YY-A8LH. In addition, a tumor/normal pair whose tumor BAM file was damaged beyond recovery was removed from the
final freeze list.
6. Filtering by ‘‘panel-of-normals’’: The sites of detected SNVs and InDels were examined against a panel of 8313 normal samples
(PoN). For a given SNV or InDel, a likelihood score that the allele counts are consistent with expectation of observed normals at
the site is calculated. Candidate mutations with a likelihood score less than -2.5 were removed from subsequent analysis. We
also removed variants outside coding regions. Additionally, any SNV or InDel that validated in either RNASeq or KRAS deep
sequencing was not filtered. As a result of ‘‘panel-of-normals’’ filtering, 7804 SNVs and InDels were removed from the call set.
7. Filtering by ExAC: 60706 germlinemutation calls from the ExAC database (http://exac.broadinstitute.org/) were used to screen
for germline calls where coverage in normal was low, and consequently, 19 SNVs and InDels were removed from the call set.
Manual Review of Variants
Following Firehose processing, we performed manual review of several significantly mutated genes using the Integrative
Genomics Viewer (IGV) (Thorvaldsdottir et al., 2013) for the review of sequencing evidence in the tumor and normal samples. Wee5 Cancer Cell 32, 185–203.e1–e13, August 14, 2017
used a representative panel of normal WES BAMs to model a wide range of sequencing or alignment artifacts, or rare germline mu-
tations, that might be misidentified as somatic mutations.
Multi-Center Calling of Mutations
To strengthen confidence in mutation calls, SNV’s and InDels were called at multiple centers within the TCGA network. SNV’s were
called at the Broad Institute, Baylor College of Medicine Human Genome Sequencing Center (HGSC), British Columbia Genome
sequencing Center (BCGSC) and the University of California Santa Cruz (UCSC). InDels were called at the Broad Institute, HGSC
and BCGSC. The final list of mutation calls for the cohort were determined as follows: 1) SNVs were accepted if called at the Broad
Institute and/or 2 or more additional centers; 2) InDels were accepted if called in 2 or more centers.
Mutation Annotation Format (MAF) File
The MAF file was generated per TCGA specifications (https://wiki.nci.nih.gov/display/TCGA/Mutation+Annotation+Format+
(MAF)+Specification) and has beenmade available with the analyses containedwithin thismanuscript. A unique column named ‘‘usa-
ble_in_mutsig’’ was added to the MAF file, and this binary valued column indicates whether a given SNV or InDel was included in the
downstream MutSig2CV analysis. 19956 SNVs and InDels in the hyper-mutated tumor sample, IB-7651, and 104 SNVs that were
discovered in the targeted panel were not included the MutSig2CV analysis; the rest of SNVs and InDels were included (see below).
Mutation Significance Analysis
Genes with a significant excess of the number of non-synonymous mutations relative to the estimated density of background mu-
tations were identified using the MutSig algorithm (Lawrence et al., 2013, 2014). MutSig has been previous used to identify signifi-
cantly mutated genes (SMGs) in several tumor sequencing projects (Berger et al., 2012; Dulak et al., 2013; Lohr et al., 2012; Stransky
et al., 2011) and the algorithm’s current version MutSig2CV (Lawrence et al., 2014) was used in this study to produce a robust list of
significantly mutated genes. MutSig takes into account the background mutation rates of different mutation categories (i.e. transi-
tions or transversions in different sequence contexts, the non-synonymous to synonymous mutation ratio for each gene, as well
as the fact that different samples have different background mutation rates. It then uses convolutions of binomial distributions to
calculate the p value for each gene, which represents the probability that we observe a certain configuration of mutations in a
gene by chance, given the background model. Finally, it corrects for multiple hypotheses by calculating a q-value (False Discovery
Rate) for each gene using the Benjamini & Hochberg procedure to produce the list of SMGs (Figures 1 and S1).
KRAS Wild-type (WT) Analysis
KRAS gene mutations were not identified in 10 of the 150 cancers, despite deep sequencing with three different approaches. To
identify other possible molecular drivers in these cancers, we conducted a thorough investigation of mutations, copy number al-
terations and translocation events in a gene set (Table S4) comprised of RAS pathway, significantly mutated, and other known
cancer genes (Figure 3A). RAS pathway genes were curated from the National Cancer Institute RAS pathway gene list, version
2.0. Significantly mutated genes were taken from the MutSig2CV analysis of the pancreatic cancer cohort presented in this manu-
script. Additional known cancer genes were taken from the Dana-Farber Cancer Institute clinical sequencing gene set (OncoPanel
v3.0). The union of these gene lists is presented in Table S4. This gene set was used to specifically interrogate for somatic muta-
tions, germline mutations in a select set of familial risk genes as indicated in the manuscript, copy number alterations and trans-
location events (from RNA, as described below). RPPA data was also interrogated within KRAS wild-type samples as discussed in
the text.
Mutation Clonality Assessment
To assess whether mutations are clonal (i.e. present in all cancer cells), we estimated the cancer cell fraction (CCF) of eachmutation,
as described (Carter et al., 2012). Mutations for which the CCF is close to 1 are considered clonal. Those mutations with lower prob-
able CCFs are considered subclonal. To determine the CCF we first calculated the sample purity (i.e. the percentage of tumor cells in
our sample) using the ABSOLUTE program to estimate sample purity and ploidy based on whole exome sequencing array data for
allele specific copy number measurement and mutation allele fraction information (Carter et al., 2012).
Once we had estimated tumor purity and ploidy for the 150 samples, we then calculated the cancer cell fraction (CCF) for each
mutation. The cancer cell fraction is the percentage of tumor cells harboring a given mutation. Clonal mutations have an underlying
cancer cell fraction of one and subclonal mutations have an underlying cancer cell fraction of less than one. Mutations were classified
as subclonal if the upper bound of the 95% confidence interval was less than 0.9 and clonal if the lower bound of the 95% confidence
interval exceeded 0.9.
Copy Number Analysis
For copy number analysis based on exome sequencing, segmented copy data was obtained using copy number ratios. These
were calculated as the ratio of tumor read depth to the average read depth observed in a panel of normal samples using the
tool, RECAPSEG5. Allelic copy number analysis was done with Allelic-Capseg using B-allele frequencies from heterozygous sites
ABSOLUTE (Carter et al., 2012) was used to determine purity, ploidy, and whole genome doubling status using allelic copy number
data along with the allelic fraction of all somatic mutations as input. In silico admixture removal (ISAR) was used to perform purity
and ploidy correction of the RECAPSEG data. We used ABSOLUTE derived copy number from WES to identify genes with loss ofCancer Cell 32, 185–203.e1–e13, August 14, 2017 e6
heterozygosity and homozygous deletions. High level amplifications were defined as those genes with three or more copies above
baseline ploidy.
SCNA Significance Analysis
Significance of copy number alterations were assessed from the segmented data using GISTIC2.0 (Version 2.0.22) (Mermel et al.,
2011). Briefly, GISTIC2.0 deconstructs somatic copy-number alterations into broad and focal events and applies a probabilistic
framework to identify location and significance levels of somatic copy-number alterations. For the purpose of this analysis, we
defined an arm-level event as any event spanning more than 50% of a chromosome arm.
SCNA Clustering
For copy number clustering, the cohort was dichotomized into one group above the median purity and one below. The high-purity
tumors were clustered based on log2 copy number at regions revealed by GISTIC analysis. Clustering was done in R, with an
Euclidean distance using Ward’s method. The same matrix used for the high-purity group was then applied to the low purity group.
This allowed for the merger of the two by combining clusters that showed the same marker SCNAs. Of note, a group of 20 low-purity
tumors had no SCNAs and were thus referred to as ‘NO’ in the clustering analysis.
Germline Variant Calling, QC, and Analysis
Germline variants were interrogated for 13 genes that are examined in patients with a significant family history of pancreatic cancer at
the Dana-Farber Cancer Institute, including BRCA1, BRCA2, PALB2, STK11, CDKN2A, ATM, PRSS1, MLH1, MSH2, MSH6, PMS2,
EPCAM and TP53. Briefly, germline variants were identified in these genes that occur in < 1%of the normal population, annotated for
predicted functional impact and cross-referenced with the ClinVar database for prior evidence of disease linkage.
A total of 150 germline exomes from the study were called using best practices with the Genome Analysis Toolkit (GATK) Haplo-
typeCaller (version 3.6)(McKenna et al., 2010). The calls were then combined and jointly genotyped, and the sites were filtered
through the GATK Variant Quality Score Recalibration (VQSR) workflow as recommended in GATK Best Practices (http://
gatkforums.broadinstitute.org/gatk/discussion/1259/which-training-sets-arguments-should-i-use-for-running-vqsr).
Principal components analysis (PCA) was then performed on the resulting callset using a subset of 5,856 variants chosen by Purcell
and others (Purcell et al., 2014) such that they were (i) on autosomal chromosomes; (ii) polymorphic across multiple ethnic popula-
tions; (iii) present in the targeted coding regions of most exome capture platforms; (iv) in approximate linkage equilibrium; and (v) in
Hardy-Weinberg equilibrium. We combined the 150 PAAD germline exomes with a set of 1489 publicly available, normal population
exomes with known ethnicity labels from the 1000 Genomes Project and the Exome Sequencing Project study.
Using EIGENSTRAT’s smartpca in fastmode (Price et al., 2006), we obtained 10 principal component vectors, and using the known
ethnicity annotations for the normal population samples as a training set, we inferred the ethnicity of the PAAD cohort samples based
on their projection onto the first five principal components (PCs). For each of the labeled ethnic groups, we calculated the center in the
five-principal component space and assigned samples with unknown ethnicity based on the closest centroid (using Euclidean dis-
tance). We next examined cryptic relatedness within the PAAD cohort, running KING (Manichaikul et al., 2010) on the same set of
5,856 sites to check for duplicates and first- or second-degree relatives in the cohort. None were found.
Next, we assessed a battery of sample-level quality control (QC) metrics from the calling process, including the total number of
single nucleotide variants (SNVs) and insertions/deletions (indels) called, transition-transversion ratios, and the number of singleton
and novel sites. The distribution of each sample QC metric was evaluated for outliers within each ethnicity group (African American,
Asian, European American, and Hispanic). None were found.
Germline variants in the 13 selected genes were extracted from the callset, and common variants (with minor allele frequency > 1%
in the non-cancer ExAC normal population cohort (ftp://ftp.broadinstitute.org/pub/ExAC_release/release0.3.1/subsets/)) were
removed. All genotype calls with a genotype quality score less than 20 (the phred-scaled confidence in the genotype call) were
removed. We used the variant effect predictor (VEP) (http://www.ensembl.org/info/docs/tools/vep/index.html) with the LOFTEE plu-
gin (https://github.com/konradjk/loftee) to annotate all variant sites for their expected functional impact. Missense mutations were
only reported if there was prior reported evidence of functional significance in the ClinVar database.
KRAS Validation by Resequencing
Validation ofKRASmutations was performed by targeted resequencing usingmicrofluidic PCR on the 48.48 Fluidigm Access system
(Fluidigm, South San Francisco, CA) and the MiSeq sequencing system (Illumina, San Francisco, CA). Tumor samples were selected
for validation based on the presence of the indicated mutations by whole exome sequencing. In addition, a subset of normals was
also chosen for re-sequencing. Target-specific primers were designed to flank 2 sites of interest (chr 12: hg19 25398284-25398285
and chr 12: 25380272-25380276). Eight primer pairs were designed (five for the first target and three for the second), with target re-
gions ranging in size from 166 to 195 bp. PCR was performed on the Fluidigm Access Array according to the manufacturer’s instruc-
tions, using the single-plex protocol. The Access Array Integrated Fluidic Circuit (IFC) enabled parallel amplification of up to 48 unique
samples per chip. Every reaction combined both an amplicon-tagging PCR using tailed target-specific primers (tailed with adapter
sequence), and a molecular barcoding PCR, using primers containing sequence complementary to the target-specific primer tails, a
molecular barcode, and a flow cell attachment sequence that was compatible with Illumina. The Bravo Automated Liquid Handler
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were harvested for each sample from the chip into a single collection well, quantified, and quality-checked using Caliper GX (Perkin
Elmer, Boston, MA). These per-sample-amplicon-pools were then normalized based on concentration, and pooled into a single tube
(usually 96 samples per pool, but variable). Final amplicon library pools were quantified by qPCR using the Kapa Library Quantifica-
tion Kit for NGS (Kapa Biosystems, Wilmington, MA), and sequenced on MiSeq according to manufacturer’s protocol using paired
end 150-bp sequencing reads. Output from Illumina software is processed by the Picard data-processing pipeline to yield BAM files
containing well-calibrated, aligned reads.
Custom Targeted Gene Panel Sequencing
Library construction was performed as described by Fisher et al. (Fisher et al., 2011) with some slight modifications. Initial genomic
DNA input into shearing was reduced from 3mg to 100ng in 50mL of solution. In addition, for adapter ligation, Illumina paired end
adapters were replaced with palindromic forked adapters with unique 8 base index sequences embedded within the adapter.
In-solution hybrid selection was performed using a custom design panel Illumina Rapid Capture enrichment kit with 43,164bp
target territory (0.43 Mb baited). Dual-indexed libraries are pooled into groups based on library construction performance prior to
hybridization. The liquid handling is automated on a Hamilton Starlet. The enriched library pools are quantified via PicoGreen after
elution from streptavadin beads and then normalized to a range compatible with sequencing template denature protocols. Resulting
libraries were sequenced on Illumina HiSeq2500 instruments with paired in 76bp reads. Output from Illumina software is processed
by the Picard data-processing pipeline to yield BAM files containing well-calibrated, aligned reads.
RNA-Sequencing (RNA-seq)
RNA Library Construction, Sequencing, and analysis
One mg of total RNA was converted to mRNA libraries using the lllumina mRNA TruSeq kit (RS-122-2001 or RS-122-2002) following
the manufacturer’s directions. Libraries were sequenced 48x7x48bp on the Illumina HiSeq 2000. FASTQ files were generated by
CASAVA. RNA reads were aligned to the hg19 genome assembly using MapSplice 0.7.4 (Wang et al., 2010). Gene expression
was quantified for the transcript models corresponding to the TCGA GAF2.1 (http://tcga-data.nci.nih.gov/docs/GAF/GAF.hg19.
June2011.bundle/outputs/TCGA.hg19.June2011.gaf), using RSEM (Li and Dewey, 2011) and normalized within-sample to a fixed
upper quartile. For further details on this processing, refer to Description file at the DCC data portal under the V2_MapSpliceRSEM
workflow (https://tcga-data.nci.nih.gov/tcgafiles/ftp_auth/distro_ftpusers/anonymous/tumor/tgct/cgcc/unc.edu/illuminahiseq_
rnaseqv2/rnaseqv2/unc.edu_PAAD.IlluminaHiSeq_RNASeqV2.mage-tab.1.0.0/DESCRIPTION.txt) or our alignment pipeline sum-
mary at CGHUB (https://cghub.ucsc.edu/docs/tcga/UNC_mRNAseq_summary.pdf).
Quantification of genes, transcripts, exons and junctions can be found at the TCGA Data Portal (https://tcga-data.nci.nih.gov/
tcga/).
mRNA Analysis
Samples were classified into groups based on mRNA expression in three ways, based on the results in Moffitt et al. (Moffitt et al.,
2015), Collisson et al. (Collisson et al., 2011), or Bailey et al. (Bailey et al., 2016). We first considered Moffitt et al.’s tumor-specific
gene expression signatures, which define classical and basal-like subtypes of pancreatic ductal adenocarcinoma (PDAC). Using
50 (48 with a unique match in our data) tumor-specific transcripts from Moffitt et al., we applied consensus clustering to our
mRNA cohort with Pearson correlation as the internal distance metric, seeking and reproducing two clusters of both genes and
samples. We then considered the four PDAC subtypes described by Bailey et al.: squamous, pancreatic progenitor, ADEX, and
immunogenic. Using the list of 613 (463 with a unique match in our data) differentially expressed transcripts from their multiclass
SAM analysis, we performed consensus clustering with mRNA from our cohort, again using Pearson correlation as the internal dis-
tance metric. We verified that the four groups of samples and transcripts that we observed reflected the up/down relationships
described in the t-statistics given for each gene and each class in the Bailey et al. manuscript. Using 62 (61 with a unique match
in our data) transcripts identified by Collisson et al., we performed consensus clustering with mRNA from our cohort, again using
Pearson correlation as the internal distance metric, seeking and verifying the presence of three clusters: classical, quasimesenchy-
mal and exocrine-like.
RNA-seq Read Mapping for lncRNAs
RNA sequence reads were aligned to the human reference genome (hg38) and transcriptome (Ensembl v.82) using STAR v.2.4.2a
(Dobin et al., 2013). STAR was run with the following parameters: minimum / maximum intron sizes were set to 30 and 500,000,
respectively, noncanonical, unannotated junctions were removed, maximum tolerated mismatches was set to 10, and the
outSAMstrandField intron motif option was enabled. The Cuffquant command included with Cufflinks v.2.2.1 (Trapnell et al.,
2010) was used to quantify the read abundances per sample, with fragment bias correction and multiread correction enabled. All
other options were set to default. To calculate the fragments per kilobase of exon per million fragments mapped (FPKM), the Cuff-
norm command was used with default parameters. From the FPKM matrix for the 76 high-purity tumor samples, we extracted 8167
genes with Ensembl biotypes that were either ‘‘lincRNA’’ or ‘‘processed_transcript’’.
lncRNA Unsupervised and Supervised clustering
For the n = 76 high-purity subset of the tumour cohort we extracted 360 lncRNAs that were robustly expressed (mean FPKMR1) and
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of samples that had similar abundance profiles by unsupervised consensus clustering with ConsensusClusterPlus (CCP) v1.24.0.
Calculations were performed using Pearson correlations, partitioning around mediods (PAM), 10000 iterations, and a random
95% fraction of genes in each iteration. We selected a five-cluster solution. To generate an abundance heatmap we identified
lncRNAs that had a mean FPKM ofR 5 and a SAM multiclass q-value of% 0.01 across the unsupervised clusters (see differential
abundance, below), transformed each row of thematrix by log10(FPKM + 1), then used the pheatmap R package (v1.0.2) to scale and
cluster only the rows, using a Pearson correlation distance metric and Ward clustering.
We identified genes that were differentially abundant across the five unsupervised clusters using a SAMmulticlass analyses (samr
v2.0) (Li and Tibshirani, 2013), with an FPKM input matrix and an FDR threshold of 0.05.
We compared unsupervised clusters to clinical and molecular covariates by calculating contingency table association p values
using R, with a Fisher exact or Chi-square test for categorical data (e.g. gender), and a Kruskal-Wallis test for real-valued data
(e.g. purity).
For supervised clustering the full set of n = 150 tumor samples, we identified the set of lncRNA which 1) were among the 360
robustly expressed lncRNA discussed earlier, 2) had a mean abundance in the high purity subset larger than the mean abundance
in the low purity subset, and 3) were differentially expressed between the 2 classes in the high purity cohort (t-test, with a B-H cor-
rected FDR of 0.1). This resulted in 86 transcripts, which were used to perform consensus clustering on the full 150 sample data set
with Pearson correlation as the internal distance metric, seeking and verifying the presence of two clusters.
mRNA Analysis of Fusion Genes
Somatic rearrangements were detected by the STAR-Fusion Firehose tool (version STAR-Fusion5 16 based on codebase: Version
0.5.1 )’’>https://github.com/STAR-Fusion Version 0.5.1) from RNA-sequencing tumor data. Three or more supporting paired-end
reads were required for event detection.
miRNA Sequencing
miRNA Libraries and Sequencing
We generated microRNA sequence (miRNA-seq) data for using methods described in (Chu et al., 2016). We aligned reads to the
GRCh37/hg19 reference human genome, and annotated read count abundance to miRBase v16 stem-loops and mature strands,
using only exact-match read alignments. Note that the BAM files available from the Genomic Data Commons (https://gdc.cancer.
gov/) include all sequence reads. We used miRBase v20 to assign 5p and 3p mature strand (miR) names to miRBase MIMAT acces-
sion IDs.
Unsupervised and Supervised Clustering
For unsupervised clustering with the n = 76 high-purity tumour samples, we used unsupervised non-negative matrix factorization
(NMF) consensus clustering (v0.20.5) in R 3.1.2, with default settings (Gaujoux and Seoighe, 2010). The input was a reads-per-million
(RPM) data matrix for the 303 (25%) most-variant 5p or 3p mature strands. After running a rank survey with 50 iterations per solution,
we chose a 3-cluster solution and performed a 500-iteration run to generate the final clustering result. To visualize typical vs. atypical
cluster members, we calculated a profile of silhouette widths from the final NMF consensusmembershipmatrix, considering samples
with relatively low widths to be atypical cluster members.
To generate a heatmap for the 3-cluster solution, we first identified miRs that were differentially abundant between the unsuper-
visedmiRNA clusters, using a SAMseqmulticlass analysis (samr 2.0)(Alexandrov et al., 2013) in R, with a read-count input matrix and
an FDR threshold of 0.05. For the heatmap, we included miRs that had the largest SAMseq scores and median abundances greater
than 25 RPM. The RPM filtering acknowledged potential sponge effects from competitive endogeneous RNAs (ceRNAs) that can
make weakly abundant miRs less influential (Mullokandov et al., 2012). We transformed each row of the matrix by log10(RPM + 1),
then used the pheatmap R package (v0.7.7 or v1.0.2) to scale and cluster only the rows, using a Pearson distance metric and
Ward clustering.
For supervised clustering the full set of n = 150 tumor samples, we identified the set of miRNA which 1) were among the 303
robustly expressed lncRNA discussed earlier, 2) had a mean abundance in the high purity subset larger than the mean abundance
in the low purity subset, and 3) were differentially expressed between the 3 classes in the high purity cohort (one class vs all t-test, with
a B-H corrected FDR of 0.1). This resulted in 31 transcripts which were used to perform consensus clustering on the full 150 sample
data set with Pearson correlation as the internal distance metric, seeking and verifying the presence of three clusters.
DNA Methylation
Assay Platform
DNA methylation data were generated using the Illumina Infinium DNA methylation platform (Bibikova et al., 2009, 2011),
HumanMethylation450 (HM450). The HM450 assay analyzes the DNA methylation status of up to 482,421 CpG and 3,091 non-
CpG (CpH) sites throughout the genome. It covers 99% of RefSeq genes with multiple probes per gene, as well as 96% of CpG
islands from the UCSC database and their flanking regions. The assay probe sequences and information for each interrogated
CpG site on Infinium DNA methylation platform are available from Illumina (www.illumina.com).
The DNA methylation score for each assayed CpG or CpH site is represented as a beta (b) value (b = (M/(M+U)) in which M and
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from zero to one, with scores of ‘‘0’’ indicating noDNAmethylation and scores of ‘‘1’’ indicating complete DNAmethylation. An empir-
ically derived detection P value accompanies each data point and compares the signal intensity with an empirical distribution of
signal intensities from a set of negative control probes on the array. Any data point with a corresponding p value greater than
0.05 is deemed not to be statistically significantly different frombackground and is thusmasked as ‘‘NA’’ in the Level 3 data packages
as described below. Further details on the Illumina Infinium DNA methylation assay technology have been described previously (Bi-
bikova et al., 2009, 2011).
Sample and Data Processing
We performed bisulfite conversion on 1mg of genomic DNA from each sample using the EZ-96 DNA Methylation Kit (Zymo
Research, Irvine, CA) according to the manufacturer’s instructions. We assessed the amount of bisulfite-converted DNA and
completeness of bisulfite conversion using a panel of MethyLight-based quality control (QC) reactions as previously described
(Campan et al., 2009). All the TCGA samples passed our QC tests and entered the Infinium DNA methylation assay pipeline.
Bisulfite-converted DNAs were whole-genome-amplified (WGA) and enzymatically fragmented prior to hybridization to BeadChip
arrays. BeadArrays were scanned using the Illumina iScan technology to produce IDAT files. Raw IDAT files for each sample
were processed with the R/Bioconductor package methylumi. TCGA DNA methylation data packages were then generated
using the EGC.tools R package which was developed internally and is publicly available on GitHub (https://github.com/
uscepigenomecenter/EGC.tools).
TCGA Data Packages
The data levels and the files contained in each data level package are described below and are present in the NCI Genomic Data
Commons (https://gdc.cancer.gov) legacy archive section (https://gdc-portal.nci.nih.gov/legacy-archive).
Level 1 data contain raw IDAT files (two per sample) as produced by the iScan system and as mapped by the Sample and Data
Relationship Format (SDRF). These IDAT files were directly processed by the R/Bioconductor package methylumi. Level 2 data
contain background-corrected methylated (M) and unmethylated (U) summary intensities as extracted by the R/Bioconductor
package methylumi. Detection P values were computed as the minimum of the two values (one per methylation state measure-
ment) for the empirical cumulative density function of the negative control probes in the appropriate color channel. Background
correction was performed via normal-exponential deconvolution (Triche et al., 2013). Multiple-batch archives had the intensities
in each of the two channels multiplicatively scaled to match a reference sample. The reference sample is defined in each array as
the sample having R/G ratio of the normalization control probes closest to 1. Level 3 data contain b-value calculations with an-
notations for HGNC gene symbol, chromosome, and genomic coordinates (UCSC hg19, Feb 2009) for each targeted CpG/CpH
site on the array. Probes having a common SNP (dbSNP build 135, Minor Allele Frequency > 1%) within 10 bp of the interrogated
CpG site or having an overlap with a repetitive element (as detected by RepeatMasker and Tandem Repeat Finder based on
UCSC hg19, Feb 2009) within 15 bp (from the interrogated CpG site) were masked as ‘‘NA’’ across all samples, and probes
with a detection P value greater than 0.05 in a given sample were masked as ‘‘NA’’ on that array. Probes that were mapped
to multiple sites in the human genome (UCSC hg19, Feb 2009) were annotated as ‘‘NA’’ for chromosome and 0 for CpG/CpH
coordinate.
Data from the following archives were used for the analyses described in this manuscript.
jhu-usc.edu_PAAD.HumanMethylation450.Level_3.2.11.0
jhu-usc.edu_PAAD.HumanMethylation450.Level_3.3.11.0
jhu-usc.edu_PAAD.HumanMethylation450.Level_3.4.11.0
jhu-usc.edu_PAAD.HumanMethylation450.Level_3.5.11.0
jhu-usc.edu_PAAD.HumanMethylation450.Level_3.6.11.0
jhu-usc.edu_PAAD.HumanMethylation450.Level_3.7.11.0
jhu-usc.edu_PAAD.HumanMethylation450.Level_3.8.11.0
jhu-usc.edu_PAAD.HumanMethylation450.Level_3.9.11.0
jhu-usc.edu_PAAD.HumanMethylation450.Level_3.10.11.0
jhu-usc.edu_PAAD.HumanMethylation450.Level_3.11.11.0
jhu-usc.edu_PAAD.HumanMethylation450.Level_3.12.11.0
Leukocyte DNA Methylation Data
Leukocyte DNA were extracted from peripheral blood samples from two healthy 59-year-old (PBL #1) and 63-year-old (PBL #2) fe-
male subjects (HemaCare, Van Nuys, CA). DNA methylation data were then generated using the HM450 platform (Table S5).
DNA Methylation Analysis
We removed probes which had any ‘‘NA’’-masked data points and probes that were designed for sequences on X and Y chromo-
somes. We split 150 tumors into two groups: those with higher purity (n = 76) and those with lower purity (n = 74) as described above.
As controls for cancer-specific DNA hypermethylation we used 7 samples that were excluded from the data freeze after the expert
pathology review (F2-7273-01, F2-7276-01, HZ-7920-01, HZ-7923-01, IB-AAUV-01, IB-AAUW-01, RL-AAAS-01). Those cases
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Unsupervised Clustering Analysis of DNA Methylation Data
We first performed unsupervised clustering analysis using the higher purity cases.We selected CpG sites that were not methylated in
the controls (mean b-value < 0.2). To minimize the influence of variable tumor purity levels on a clustering result, we dichotomized the
data using a b-value of > 0.25 to define positive DNA methylation and%0.25 to specify lack of methylation. The dichotomization not
only ameliorated the effect of tumor sample purity on the clustering, but also removed a great portion of residual batch/platform ef-
fects that are mostly reflected in small variations near the two ends of the range of b-values. Finally, we removed CpG sites that are
methylated in leukocytes, which was a major source of contamination in tumor samples (mean b-value > 0.2). We then performed
consensus clustering with the dichotomized data on 31,956 CpG sites that were methylated in at least 5% of the tumor samples.
The optimal number of clusters was assessed based on 80% probe and tumor resampling over 1,000 iterations of hierarchical
clustering for K=2,3,4,5,6 using the binary distance metric for clustering and Ward’s method for linkage as implemented in the
R/Bioconductor ConsensusClusterPlus package. The heatmap was generated based on the original b-values for a subset of the
most variably methylated sites. The probes and tumors were displayed based on the order of unsupervised hierarchal clustering
of the dichotomous data using the binary distance metric and Ward’s linkage method. The 5,000 CpG sites that showed the most
variable DNA methylation levels across the higher purity sample set were then used for unsupervised clustering of the lower purity
tumor samples, after dichotomizing the data using a b-value of > 0.2 to define positive DNA methylation.
Identification of Epigenetically-Silenced Genes
Probes that were located in a promoter region (defined as the 3 kb region spanning from 1,500 bp upstream to 1,500 bp downstream
of the transcription start sites) were identified. Level 3 RNA-seq RSEM data were log2-transformed [log2 (RSEM+1)] and used to
assess the expression levels associated with DNA methylation changes. DNA methylation and gene expression data were merged
by Entrez Gene IDs. We removed the CpG sites that were methylated in the control samples (mean b-value > 0.2). We then dichot-
omized the DNA methylation data using a b-value of > 0.3 to definite positive DNA methylation, and further eliminated CpG sites
methylated in fewer than 3% of the tumor samples. For each probe/gene pair, we applied the following algorithm: 1) classify the tu-
mors as either methylated (b > 0.3) or unmethylated (b%0.3); 2) compute the mean expression in the methylated and unmethylated
groups; 3) compute the standard deviation of the expression in the unmethylated group.We then selected probes for which themean
expression in the methylated group was lower than 1.64 standard deviations of the mean expression in the unmethylated group. We
labeled each individual tumor sample as epigenetically silenced for a specific probe/gene pair selected from above if: a) it belonged to
the methylated group and b) the expression of the corresponding gene was lower than the mean of the unmethylated group of sam-
ples. If there weremultiple probes associated with the same gene, a sample identified as epigenetically silenced at more than half the
probes for the corresponding genewas also labeled as epigenetically silenced at the gene level. Furthermore, we identified additional
genes including CDKN2A and BRCA1 having evidence for epigenetic silencing at low frequencies based on manual examination of
scatter plots of DNA methylation vs. expression. CDKN2A DNA methylation status was assessed based on the probe (cg13601799)
located in the p16INK4 promoter CpG island. p16INK4 expression was determined by the log2(RPKM+1) level of its first exon
(chr9:21974403-21975038).
Tumor Purity Assessments Based on DNA Methylation Data
We identified 1,859 CpG sites that were unmethylated in controls and leukocytes (mean b-value < 0.2) butmethylated (b-value > 0.25)
in more than 90% of the tumors in the high purity group. We then obtained the mode DNA methylation value for these hypermethy-
lated loci in each tumor. The mode DNA methylation values were strongly correlated with the ABSOLUTE purity estimates derived
from DNA copy number data (r2 = 0.73, p < 2.2 310-16).
Leukocyte fraction in each tumor was estimated using the PBL DNAmethylation data as described previously (Carter et al., 2012).
Reverse Phase Protein Arrays (RPPA)
RPPA Experiments and Data Processing
Protein was extracted using RPPA lysis buffer (1% Triton X-100, 50 mmol/L Hepes (pH 7.4), 150 mmol/L NaCl, 1.5 mmol/L MgCl2,
1 mmol/L EGTA, 100 mmol/L NaF, 10 mmol/L NaPPi, 10% glycerol, 1 mmol/L phenylmethylsulfonyl fluoride, 1 mmol/L Na3VO4, and
aprotinin 10 mg/mL) from human tumors and RPPA was performed as described previously (Hennessy et al., 2010; Hu et al., 2007;
Liang et al., 2007; Tibes et al., 2006). Lysis buffer was used to lyse frozen tumors by Precellys homogenization. Tumor lysates were
adjusted to 1 mg/mL concentration as assessed by bicinchoninic acid assay (BCA) and boiled with 1% SDS. Tumor lysates were
manually serial diluted in two-fold of 5 dilutions with lysis buffer. An Aushon Biosystems 2470 arrayer (Burlington, MA) printed
1,056 samples on nitrocellulose-coated slides (Grace Bio-Labs). Slides were probed with 192 validated primary antibodies (Table
S7) followed by corresponding secondary antibodies (Goat anti-Rabbit IgG, Goat anti-Mouse IgG or Rabbit anti-Goat IgG). Signal
was captured using a DakoCytomation-catalyzed system and DAB colorimetric reaction. Slides were scanned in CanoScan
9000F. Spot intensities were analyzed and quantified using Microvigene software (VigeneTech Inc., Carlisle, MA), to generate
spot signal intensities (Level 1 data). The software SuperCurveGUI (Hu et al., 2007) available at http://bioinformatics.mdanderson.
org/Software/supercurve/, was used to estimate the EC50 values of the proteins in each dilution series (in log2 scale). Briefly, a fitted
curve (‘‘supercurve’’) was plotted with the signal intensities on the Y-axis and the relative log2 concentration of each protein on the
X-axis using the non-parametric, monotone increasing B-spline model (Tibes et al., 2006). During the process, the raw spot intensity
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the slide: if the score is less than 0.8 on a 0-1 scale, the slide was dropped. In most cases, the staining was repeated to obtain a high
quality score. If more than one slide was stained for an antibody, the slide with the highest QC score was used for analysis (Level
2 data). Protein measurements were corrected for loading as described (Gonzalez-Angulo et al., 2011; Hu et al., 2007) using median
centering across antibodies (level 3 data). In total, 192 antibodies and 76 samples were used. Final selection of antibodies was also
driven by the availability of high quality antibodies that consistently pass a strict validation process as previously described (Hen-
nessy et al., 2010). These antibodies are assessed for specificity, quantification and sensitivity (dynamic range) in their application
for protein extracts from cultured cells or tumor tissue. Antibodies are labeled as validated and use with caution based on degree
of validation by criteria previously described (Hennessy et al., 2010).
RPPA arrays were quantitated and processed (including normalization and load controlling) as described previously, using
ArrayPro software (MediaCybernetics, Rockville, MD) and the R package SuperCurve (version-1.3), available at http://
bioinformatics.mdanderson.org/OOMPA (Hu et al., 2007; Tibes et al., 2006) . Raw data (level 1), SuperCurve nonparameteric model
fitting on a single array (level 2), and loading corrected data (level 3) were deposited at the DCC.
Data Normalization
We performed median centering across all the antibodies for each sample to correct for sample loading differences. Those differ-
ences arise because protein concentrations are not uniformly distributed per unit volume. That may be due to several factors,
such as differences in protein concentrations of large and small cells, differences in the amount of proteins per cell, or heterogeneity
of the cells comprising the samples. By observing the expression levels across many different proteins in a sample, we can estimate
differences in the total amount of protein in that sample vs. other samples. Subtracting themedian protein expression level forces the
median value to become zero, allowing us to compare protein expressions across samples.
Hierarchical Clustering in High Purity Samples
For high purity samples, we used ConsensusClusterPlus to cluster the samples, as well as estimate the number of clusters. We used
(1 - Pearson correlation) as the distance metric and Ward as a linkage algorithm in the unsupervised hierarchical clustering analysis.
To illustrate the role of cell signaling network in pancreatic cancer, we calculated 9 pathway scores (Table S7) based on a previously
described method (Akbani et al., 2014).
Integrative Quantitative Analysis (IQA)
For Integrative quantitative analysis (IQA), we analyzed tumor samples in either the high (n = 76) and low (n = 74) purity groups sepa-
rately. In each of the two groups separately, the top 50% expressed mRNAs, lncRNAs and miRNAs were considered and Spearman
correlation coefficients were calculated for each of the following: (a) all miRNA-mRNA and all miRNA-lncRNA pairs, (b) each miRNA
with the methylation probes that are as far as 1,000 bp from the middle of the mature miRNA genomic coordinates on either strand of
the genome and (c) eachmRNA and lncRNAwith themethylation probes that are as far as 1,000 bp from the transcription start site of
the respective transcript on either strand of the genome. MiRNA’s from both miRBase and those that were previously reported (Lon-
din et al., 2015)(Table S6) and found expressed in the PAAD cancers were considered for analysis. Onlymethylation probes that had a
methylation value of > 0.3 in more than 3% of the samples were considered in the analysis. Calculations were done in Python 2.7
using the SciPy and NumPy packages and false discovery rate was calculated using the Benjamini-Hochberg correction procedure.
The top 1,000 negative correlations (sorted by FDR) in each group are included in Table S8. For both analyses, FDR was found to
be < 0.01. For each miRNA-mRNA pair further evidence of a direct interaction was sought: the rna22 (Miranda et al., 2006) and
TargetScan (Agarwal et al., 2015) target prediction algorithms were used to check whether the miRNA-mRNA interaction could
be predicted along with simulation data (CLIP-sim) from Argonaute HITS-CLIP from HPNE and MIA PaCa-2 model cell lines (Clark
et al., 2014). Validation data from the MiRTarBase v. 6.1 (Chou et al., 2016b; Hsu et al., 2014) were also integrated in the analysis.
Direct interaction evidence for miRNA-lncRNA pairs as calculated from rna22 (Loher and Rigoutsos, 2012; Miranda et al., 2006),
miRcode 11 (Jeggari et al., 2012) or NPInter v3.0 (Hao et al., 2016) was also integrated. DAVID (Huang da et al., 2009) was run for
the genes that were part of the network, using as background the list of genes that were initially included in the correlations, and
an FDR cutoff of 10% (Table S8). Network visualization was carried out in R using the igraph package. Differential expression
analyses for miRNAs, mRNAs and lncRNAs were carried using SAM (Tusher et al., 2001) with an FDR threshold of 0.0%
(Table S8). These three datasets were log2-transformed before the significance analysis by SAM. Differences in the methylation sta-
tus were evaluated using the non-parametric Mann-Whitney U-test and p values were corrected to FDR. To examine the cancer rele-
vance of the differentially expressed genes between the classical and the basal mRNA-defined subtypes, their overlap with the gene
sets in MsigDB v5.1 (Subramanian et al., 2005) was examined (Table S8).
Similarity Network Fusion (SNF)
Similarity network fusion (SNF)(Wang et al., 2014) was based on miRNA, mRNA, lncRNA, and DNAmethylation data from 76 individ-
uals constituting all high purity samples. RPPA data was excluded due tomultiple samples withmissing data. First, similarity matrices
were constructed using features derived from each platform individually for the purposes of clustering: for DNAmethylation, the same
5,000 CpG sites were used; for mRNA, the same 50 genes used for clustering in Moffitt et al., for lncRNA, the 86 transcripts and for
miRNA, the same 31 transcripts as described above. The miRNA, mRNA and lncRNA features were log-transformed, using log(1+x),
and then standardized. Euclidean distance was used on all four datasets to compute the corresponding distance matrices. Then,Cancer Cell 32, 185–203.e1–e13, August 14, 2017 e12
SNF transformed and combined the distance matrices from the different data types into a single matrix/network by performing graph
diffusion across all similarities between patients. The resulting matrix captures combined similarity across all platforms. Intuitively,
SNF combines all data types by keeping the strongest similarities supported by one or more types of data and the similarities sup-
ported by multiple modalities while removing similarities with weak support. We ran SNF to combine all four data types using the
following parameters values: K = 10, T = 30, a = 0.5.
SNF network figures were generated using Cytoscape. From the fused similarity matrix, only the top 10% of the weights were
considered for the network figure. The layout used from Cytoscape is edge-weighted spring embedded. The nodes’ sizes were
scaled by the absolute purity. The edges were colored to indicate the data type most supportive of the similarity. If the weights in
multiple data types are within 10% of the maximal weight we consider the edge to be supported by multiple data types.
QUANTIFICATION AND STATISTICAL ANALYSIS
Quantitative and statistical methods are noted above according to their respective technology and analytic approach.
DATA AND SOFTWARE AVAILABILITY
The data and analysis results can be explored through the Genomic Data Commons (https://gdc.cancer.gov), the Broad Institute
GDAC FireBrowse portal (http://gdac.broadinstitute.org), the Memorial Sloan Kettering Cancer Center cBioPortal (http://www.
cbioportal.org), and the PAAD publication page (https://tcga-data.nci.nih.gov/docs/publications/).e13 Cancer Cell 32, 185–203.e1–e13, August 14, 2017
